<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Mol Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Mol Neurosci</journal-id>
<journal-id journal-id-type="publisher-id">Front. Mol. Neurosci.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Molecular Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="epub">1662-5099</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30505269</article-id>
<article-id pub-id-type="pmc">6250831</article-id>
<article-id pub-id-type="doi">10.3389/fnmol.2018.00419</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Reduced Efficacy of d-Amphetamine and 3,4-Methylenedioxymethamphetamine in Inducing Hyperactivity in Mice Lacking the Postsynaptic Scaffolding Protein SHANK1</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Sungur</surname>
<given-names>A. Özge</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/489255/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Redecker</surname>
<given-names>Tobias M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/606034/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Andres</surname>
<given-names>Elena</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/595795/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dürichen</surname>
<given-names>Wiebke</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/616104/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schwarting</surname>
<given-names>Rainer K. W.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/767/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>del Rey</surname>
<given-names>Adriana</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/10287/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wöhr</surname>
<given-names>Markus</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/28506/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Behavioral Neuroscience, Experimental and Biological Psychology, Philipps University of Marburg</institution>, <addr-line>Marburg</addr-line>, <country>Germany</country></aff>
<aff id="aff2"><sup>2</sup><institution>Center for Mind, Brain and Behavior, Philipps University of Marburg</institution>, <addr-line>Marburg</addr-line>, <country>Germany</country></aff>
<aff id="aff3"><sup>3</sup><institution>Research Group Immunophysiology, Division of Neurophysiology, Institute of Physiology and Pathophysiology, Philipps University of Marburg</institution>, <addr-line>Marburg</addr-line>, <country>Germany</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Eunjoon Kim, Institute for Basic Science (IBS), South Korea</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Christian P. Müller, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany; Damiana Leo, University of Mons, Belgium</p>
</fn>
<corresp id="c001">*Correspondence: Markus Wöhr, <email>markus.woehr@staff.uni-marburg.de</email><ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0001-6986-5684">orcid.org/0000-0001-6986-5684</ext-link></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>16</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>11</volume>
<elocation-id>419</elocation-id>
<history>
<date date-type="received">
<day>01</day>
<month>8</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>10</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 Sungur, Redecker, Andres, Dürichen, Schwarting, del Rey and Wöhr.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Sungur, Redecker, Andres, Dürichen, Schwarting, del Rey and Wöhr</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Genetic defects in the three SH3 and multiple ankyrin repeat domains (SHANK) genes (<italic>SHANK1, SHANK2</italic>, and <italic>SHANK3</italic>) are associated with multiple major neuropsychiatric disorders, including autism spectrum disorder (ASD), schizophrenia (SCZ), and bipolar disorder (BPD). Psychostimulant-induced hyperactivity is a commonly applied paradigm to assess behavioral phenotypes related to BPD and considered to be the gold standard for modeling mania-like elevated drive in mouse models. Therefore, the goal of our present study was to test whether <italic>Shank1</italic> plays a role in the behavioral effects of psychostimulants and whether this is associated with genotype-dependent neurochemical alterations. To this aim, male and female null mutant <italic>Shank1<sup>-/-</sup></italic> mice were treated with d-amphetamine (AMPH; 2.5 mg/kg) and 3,4-methylenedioxymethamphetamine (MDMA, commonly known as ecstasy; 20 mg/kg), and psychostimulant-induced hyperactivity was compared to heterozygous <italic>Shank1<sup>+/-</sup></italic> and wildtype <italic>Shank1<sup>+/+</sup></italic> littermate controls. Results show that <italic>Shank1<sup>-/-</sup></italic> mice display reduced psychostimulant-induced hyperactivity, although psychostimulants robustly stimulated locomotor activity in littermate controls. <italic>Shank1</italic> deletion effects emerged throughout development, were particularly prominent in adulthood, and seen in response to both psychostimulants, i.e., AMPH and MDMA. Specifically, while AMPH-induced hyperactivity was reduced but still detectable in <italic>Shank1<sup>-/-</sup></italic> mice, MDMA-induced hyperactivity was robustly blocked and completely absent in <italic>Shank1<sup>-/-</sup></italic> mice. Reduced efficacy of psychostimulants to stimulate hyperactivity in <italic>Shank1<sup>-/-</sup></italic> mice might be associated with alterations in the neurochemical architecture in prefrontal cortex, nucleus accumbens, and hypothalamus. Our observation that psychostimulant-induced hyperactivity is reduced rather than enhanced in <italic>Shank1<sup>-/-</sup></italic> mice clearly speaks against a behavioral phenotype with relevance to BPD. Lack of BPD-like phenotype is consistent with currently available human data linking mutations in <italic>SHANK2</italic> and <italic>SHANK3</italic> but not <italic>SHANK1</italic> to BPD.</p>
</abstract>
<kwd-group>
<kwd>ecstasy</kwd>
<kwd>MDMA</kwd>
<kwd>dopamine</kwd>
<kwd>noradrenaline</kwd>
<kwd>norepinephrine</kwd>
<kwd>serotonin</kwd>
</kwd-group>
<counts>
<fig-count count="9"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="121"></ref-count>
<page-count count="22"></page-count>
<word-count count="0"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec>
<title>Introduction</title>
<p>Genetic defects in the three SH3 and multiple ankyrin repeat domains (SHANK) genes (<italic>SHANK1, SHANK2</italic>, and <italic>SHANK3</italic>) are associated with multiple major neuropsychiatric disorders, including autism spectrum disorder (ASD), schizophrenia (SCZ), and bipolar disorder (BPD; <xref ref-type="bibr" rid="B38">Guilmatre et al., 2014</xref>; <xref ref-type="bibr" rid="B6">Bourgeron, 2015</xref>; <xref ref-type="bibr" rid="B12">de la Torre-Ubieta et al., 2016</xref>). Early genetic studies provided compelling evidence implicating <italic>SHANK</italic> mutations in the whole spectrum of ASD (<xref ref-type="bibr" rid="B19">Durand et al., 2007</xref>; <xref ref-type="bibr" rid="B57">Moessner et al., 2007</xref>; <xref ref-type="bibr" rid="B32">Gauthier et al., 2009</xref>; <xref ref-type="bibr" rid="B5">Berkel et al., 2010</xref>; <xref ref-type="bibr" rid="B73">Pinto et al., 2010</xref>; <xref ref-type="bibr" rid="B84">Sato et al., 2012</xref>). However, there is increasing evidence suggesting that <italic>SHANK</italic> mutations play a prominent role in other neuropsychiatric disorders as well. For instance, <xref ref-type="bibr" rid="B27">Fromer et al. (2014)</xref> reported a <italic>de novo SHANK1</italic> frameshift mutation in a SCZ patient, and <xref ref-type="bibr" rid="B48">Lennertz et al. (2012)</xref> found that a <italic>SHANK1</italic> promotor variant is associated with reduced auditory working memory capacity in SCZ patients. Mutations in <italic>SHANK2</italic> and <italic>SHANK3</italic> have likewise been described in individuals with SCZ (<xref ref-type="bibr" rid="B31">Gauthier et al., 2010</xref>; <xref ref-type="bibr" rid="B72">Peykov et al., 2015</xref>; <xref ref-type="bibr" rid="B41">Homann et al., 2016</xref>). Moreover, a duplication in <italic>SHANK2</italic> has been reported for a BPD patient (<xref ref-type="bibr" rid="B62">Noor et al., 2014</xref>) and BPD has been diagnosed also in individuals with the Phelan-McDermid 22q13 deletion syndrome lacking <italic>SHANK3</italic> (<xref ref-type="bibr" rid="B92">Sovner et al., 1996</xref>; <xref ref-type="bibr" rid="B108">Willemsen et al., 2011</xref>; <xref ref-type="bibr" rid="B13">Denayer et al., 2012</xref>; <xref ref-type="bibr" rid="B101">Verhoeven et al., 2012</xref>, <xref ref-type="bibr" rid="B102">2013</xref>; <xref ref-type="bibr" rid="B103">Vucurovic et al., 2012</xref>). It thus appears that <italic>SHANK</italic> mutations are shared across multiple neuropsychiatric disorders similar to other genetic risk factors, pointing to extensive pleiotropy and challenging the biological validity of existing diagnostic approaches (<xref ref-type="bibr" rid="B121">Zhu et al., 2014</xref>; <xref ref-type="bibr" rid="B34">Geschwind and Flint, 2015</xref>; <xref ref-type="bibr" rid="B63">O’Donovan and Owen, 2016</xref>). However, the neurobiological mechanisms underlying the pleiotropic effects of <italic>SHANK</italic> mutations are not well understood.</p>
<p>The three <italic>SHANK</italic> genes code for several mRNA splice variants and generate multiple protein isoforms (<xref ref-type="bibr" rid="B99">Ting et al., 2012</xref>; <xref ref-type="bibr" rid="B81">Sala et al., 2015</xref>). Members of the SHANK protein family have five conserved protein domains through which they assemble into large molecular platforms in the postsynaptic density (PSD) at excitatory glutamatergic synapses. More than 30 synaptic proteins have been reported to form interactions with SHANK protein family members. As master scaffolding proteins, SHANKs anchor glutamate receptors and link them to the actin cytoskeleton and postsynaptic signaling pathways. They are thus strongly involved in several synaptic functions, including spine morphogenesis, synapse formation, glutamate receptor trafficking, and activity-dependent neuronal signaling.</p>
<p>Several <italic>Shank</italic> mouse models were generated during the last decade (<xref ref-type="bibr" rid="B46">Jiang and Ehlers, 2013</xref>; <xref ref-type="bibr" rid="B118">Yoo et al., 2013</xref>; <xref ref-type="bibr" rid="B88">Schmeisser and Verpelli, 2016</xref>). While <italic>Shank2</italic> and <italic>Shank3</italic> mutant mice have been extensively characterized (<xref ref-type="bibr" rid="B69">Peça et al., 2011</xref>; <xref ref-type="bibr" rid="B105">Wang et al., 2011</xref>; <xref ref-type="bibr" rid="B87">Schmeisser et al., 2012</xref>; <xref ref-type="bibr" rid="B113">Won et al., 2012</xref>), comparatively little is known about <italic>Shank1</italic> mutant mice (<xref ref-type="bibr" rid="B97">Sungur et al., 2018</xref>). <xref ref-type="bibr" rid="B43">Hung et al. (2008)</xref> generated <italic>Shank1</italic> mutant mice via deletion of exons 14 and 15 encoding almost the entire PDZ domain. This approach resulted in a complete knockout of all SHANK1 protein isoforms. Behavioral studies employing <italic>Shank1<sup>-/-</sup></italic> mice almost exclusively focused on ASD-related behavioral phenotypes and cognitive deficits with relevance to intellectual disability (<xref ref-type="bibr" rid="B90">Silverman et al., 2010</xref>). Specifically, <xref ref-type="bibr" rid="B43">Hung et al. (2008)</xref> performed an extensive set of cognitive tasks and found that <italic>Shank1<sup>-/-</sup></italic> mice display impaired contextual but intact cued fear memory, and enhanced acquisition but impaired retention of spatial memory, possibly resembling the aberrant cognitive phenotype present in some ASD cases. Extending these findings, we recently showed that <italic>Shank1<sup>-/-</sup></italic> mice are severely impaired in novel object recognition memory and that this deficit is associated with increased expression of brain-derived neurotrophic factor BDNF in the hippocampus, possibly due to epigenetic modifications, as indicated by enrichment of histone H3 acetylation at the <italic>Bdnf</italic> promoter1 in <italic>Shank1<sup>-/-</sup></italic> mice (<xref ref-type="bibr" rid="B95">Sungur et al., 2017</xref>). Consistent with ASD-related behavioral phenotypes, we further showed that <italic>Shank1<sup>-/-</sup></italic> mice show prominent vocal and olfactory communication deficits (<xref ref-type="bibr" rid="B112">Wöhr et al., 2011</xref>; <xref ref-type="bibr" rid="B110">Wöhr, 2014</xref>; <xref ref-type="bibr" rid="B96">Sungur et al., 2016</xref>), together with a moderate increase in self-grooming behavior (<xref ref-type="bibr" rid="B98">Sungur et al., 2014</xref>) and mild alterations in social behavior (<xref ref-type="bibr" rid="B89">Silverman et al., 2011</xref>; <xref ref-type="bibr" rid="B95">Sungur et al., 2017</xref>).</p>
<p>However, because mutations in <italic>SHANK</italic> genes are associated with multiple major neuropsychiatric disorders, including SCZ and BPD besides ASD, we reasoned that a more comprehensive characterization of <italic>Shank1<sup>-/-</sup></italic> mice might provide novel insights into the complex role <italic>SHANK1</italic> appears to play. A commonly applied paradigm to assess behavioral phenotypes related to SCZ and BPD in mouse models is psychostimulant-induced hyperactivity (<xref ref-type="bibr" rid="B47">Kato et al., 2007</xref>; <xref ref-type="bibr" rid="B120">Young et al., 2011</xref>). Psychostimulants, such as d-amphetamine (AMPH), can provoke mania-like symptoms in healthy subjects and exacerbate symptoms or induce a manic episode in BPD patients (<xref ref-type="bibr" rid="B56">Meyendorff et al., 1985</xref>; <xref ref-type="bibr" rid="B70">Peet and Peters, 1995</xref>; <xref ref-type="bibr" rid="B40">Hasler et al., 2006</xref>). AMPH-induced hyperactivity is thus considered to be the gold standard for modeling mania-like elevated drive in rodents (<xref ref-type="bibr" rid="B4">Berggren et al., 1978</xref>; <xref ref-type="bibr" rid="B36">Gould et al., 2001</xref>; <xref ref-type="bibr" rid="B71">Pereira et al., 2014</xref>). While AMPH affects primarily the catecholaminergic system and results in increased extracellular dopamine (DA) and noradrenaline (NA) concentrations through direct interaction with DA and NA transporters, other psychostimulants, such as 3,4-methylenedioxymethamphetamine (MDMA; commonly known as ecstasy), differ in their mode of action by having particularly strong effects on serotonin (5-HT) in addition (<xref ref-type="bibr" rid="B94">Sulzer et al., 2005</xref>; <xref ref-type="bibr" rid="B44">Hutson et al., 2014</xref>). Importantly, <italic>Shank3</italic> overexpression was linked to increased locomotor activity in mice and <xref ref-type="bibr" rid="B39">Han et al. (2013)</xref> found that an acute injection of AMPH aggravated the hyperactivity of <italic>Shank3</italic> overexpressing mice to a greater extent than in controls. Moreover, <xref ref-type="bibr" rid="B67">Pappas et al. (2017)</xref> recently generated <italic>Shank2</italic> mutant mice lacking exon 24 (Δ24) and found that <italic>Shank2<sup>Δ24-/-</sup></italic> mice display elevated levels of locomotor activity, which could be normalized by lithium and valproate treatment, but were further enhanced by AMPH administration. The augmentation with AMPH was more prominent in <italic>Shank2<sup>Δ24-/-</sup></italic> mice than in wildtype <italic>Shank2<sup>Δ24+/+</sup></italic> controls (<xref ref-type="bibr" rid="B67">Pappas et al., 2017</xref>).</p>
<p>Here, we therefore asked whether <italic>Shank1</italic> plays a role in the behavioral effects of psychostimulants and whether this is associated with genotype-dependent neurochemical alterations. Firstly, at the behavioral level, we assessed psychostimulant-induced hyperactivity in <italic>Shank1<sup>-/-</sup></italic> null mutant mice in comparison to heterozygous <italic>Shank1<sup>+/-</sup></italic> and wildtype <italic>Shank1<sup>+/+</sup></italic> littermate controls across development. To this aim, juvenile and adult subject mice were treated with the psychostimulant AMPH primarily targeting DA and NA transporters, and their locomotor activity was assessed in an open field. To assess specificity and to evaluate generalizability, subject mice were further treated with the psychostimulant MDMA, which has particularly strong effects on the 5-HT transporter. Secondly, at the neurobiological level, we analyzed DA, NA, and 5-HT neurotransmitter concentrations together with their precursors and metabolites in relevant brain structures, namely prefrontal cortex, nucleus accumbens, and hypothalamus.</p>
</sec>
<sec id="s1" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec>
<title>Animals and Housing</title>
<p>Juvenile and adult <italic>Shank1<sup>-/-</sup></italic> null mutant mice with a targeted replacement of exons 14 and 15 encoding almost the entire PDZ domain were compared to <italic>Shank1<sup>+/-</sup></italic> heterozygous and <italic>Shank1<sup>+/+</sup></italic> wildtype littermate control mice. Mice were obtained from mutant lines originally generated by <xref ref-type="bibr" rid="B43">Hung et al. (2008)</xref> on two independent background strains: C57BL/6J and 129SvJae. As high mortality rates were obtained in the C57BL/6J background strain and very low locomotion in the 129SvJae background strain (<xref ref-type="bibr" rid="B43">Hung et al., 2008</xref>; <xref ref-type="bibr" rid="B89">Silverman et al., 2011</xref>), the two lines were crossed for at least three generations to produce a mixed C57BL/6J/129SvJae background for the <italic>Shank1</italic> mutation. This mixed background was maintained since then and used in the present study, consistent with other studies focusing on this <italic>Shank1</italic> mutant (<xref ref-type="bibr" rid="B43">Hung et al., 2008</xref>; <xref ref-type="bibr" rid="B112">Wöhr et al., 2011</xref>; <xref ref-type="bibr" rid="B89">Silverman et al., 2011</xref>; <xref ref-type="bibr" rid="B98">Sungur et al., 2014</xref>, <xref ref-type="bibr" rid="B95">2017</xref>, <xref ref-type="bibr" rid="B97">2018</xref>; <xref ref-type="bibr" rid="B110">Wöhr, 2014</xref>). Using a heterozygous breeding protocol, <italic>Shank1<sup>+/-</sup></italic> males and females were bred in a conventional vivarium at the Biomedical Research Center of the Philipps-University of Marburg, Germany. Approximately 2 weeks after pairing for breeding, females were individually housed and inspected daily for pregnancy and delivery. The day of birth was considered as postnatal day (PND) 0. After weaning on PND21, mice were socially housed in groups of 2–6 with same-sex partners in polycarbonate Makrolon type III IVC cages (L × W × H: 420 × 265 × 180 mm, 825 cm<sup>2</sup>; Ehret, Emmendingen, Germany). Bedding and a wooden board were provided in each cage. Standard rodent chow and water were available ad libitum. The colony room was maintained on a 12:12 light/dark cycle (lights on: 06:00h) at approximately 22°C and 40–50% humidity. Pups were identified by paw tattoo, using non-toxic animal tattoo ink (Ketchum permanent Tattoo Inks green paste, Ketchum Manufacturing Inc., Brockville, ON, Canada). The ink was inserted subcutaneously through a 30 gauge hypodermic needle tip into the center of the paw. For genotyping, mouse tail snips were collected by dissecting ∼0.3 cm of tail between PND3-12. Genotyping was performed as described previously (<xref ref-type="bibr" rid="B98">Sungur et al., 2014</xref>). All procedures were approved by the ethical committee of the Regierungspräsidium Gießen, Germany [file reference: V54–19c 20 15 (1) MR20/35 Nr. 20/2010 and V54–19c 20 15 h 01 MR20/35 Nr. G 30/2018].</p>
</sec>
<sec>
<title>Experimental Design</title>
<p>For testing whether <italic>Shank1</italic> plays a role in the behavioral effects of psychostimulants, male and female null mutant <italic>Shank1<sup>-/-</sup></italic> mice were treated with AMPH (2.5 mg/kg) and MDMA (20 mg/kg), and psychostimulant-induced hyperactivity was compared to heterozygous <italic>Shank1<sup>+/-</sup></italic> and wildtype <italic>Shank1<sup>+/+</sup></italic> littermate controls. AMPH-induced hyperactivity was assessed in juvenile (<italic>Shank1<sup>+/+</sup></italic>: <italic>N</italic> = 15; <italic>Shank1<sup>+/-</sup></italic>: <italic>N</italic> = 20; <italic>Shank1<sup>-/-</sup></italic>: <italic>N</italic> = 16) and adult (<italic>Shank1<sup>+/+</sup></italic>: <italic>N</italic> = 24; <italic>Shank1<sup>+/-</sup></italic>: <italic>N</italic> = 28; <italic>Shank1<sup>-/-</sup></italic>: <italic>N</italic> = 28) mice. MDMA-induced hyperactivity was determined in adulthood only (<italic>Shank1<sup>+/+</sup></italic>: <italic>N</italic> = 14; <italic>Shank1<sup>+/-</sup></italic>: <italic>N</italic> = 19; <italic>Shank1<sup>-/-</sup></italic>: <italic>N</italic> = 14). Drug doses are expressed as salt and were determined based on previous studies reporting psychostimulant-induced hyperactivity (<xref ref-type="bibr" rid="B78">Risbrough et al., 2006</xref>; <xref ref-type="bibr" rid="B119">Young et al., 2010</xref>).</p>
</sec>
<sec>
<title>Drug Treatment</title>
<p>d-amphetamine sulfate (AMPH; Sigma–Aldrich, MO, United States) and 3,4-Methylendioxy-<italic>N</italic>-methylamphetamin (MDMA; Lipomed, Switzerland) were dissolved in 0.9% saline and administered intraperitoneally (i.p.) at volume of 1 ml/kg. As vehicle control, 0.9% saline was used. Injections were performed immediately prior to open field exposure for locomotor activity assessment.</p>
</sec>
<sec>
<title>Open Field</title>
<p>Psychostimulant-induced hyperactivity was measured in an open field (50 cm × 50 cm × 35 cm; TSE Systems, Bad Homburg, Germany) under dim red light, according to a previously established protocol (<xref ref-type="bibr" rid="B61">Natusch and Schwarting, 2010</xref>). Individual mice were placed randomly in one of the corners of the open field and were allowed to explore the apparatus for 45 min on three consecutive days. On the first day (baseline), mice were habituated to the open field. On the second day (saline), mice were administered saline. On the third day (treatment), mice were administered AMPH or MDMA. Distance traveled, rearing behavior, and the time spent in the center (30 cm × 30 cm) were automatically collected using the TSE VideoMot2 analyzer software (TSE Systems, Bad Homburg, Germany). Circling behavior, i.e., turning in a circular motion, was quantified by a trained observer.</p>
</sec>
<sec>
<title>Tissue Preparation</title>
<p>Drug-naïve juvenile mice of both sexes were individually caged and sacrificed by cervical dislocation. Immediately after the brain was removed, prefrontal cortex, nucleus accumbens, and hypothalamus were dissected using a special brain matrix, designed by Dr. J. Wildmann (Institute for Physiology and Pathophysiology, Philipps-University, Marburg). The different regions were divided into right and left parts, quickly frozen on dry ice, and stored at -80°C until used for neurotransmitter determination.</p>
</sec>
<sec>
<title>Neurotransmitter Determination</title>
<p>The concentration of catecholaminergic and indolaminergic neurotransmitters, metabolites, and precursors were measured using high performance liquid chromatography (HPLC), as previously described (<xref ref-type="bibr" rid="B79">Roggero et al., 2016</xref>). Briefly, frozen brain samples were homogenized in 0.4 M HClO<sub>4</sub> by sonication and 10 μl of the supernatant was injected for the analysis. The HPLC system used consists of a reversed-phase C-18 chromatography column (Supelco, Sigma–Aldrich, St. Louis, MO, United States) as stationary phase and an aqueous eluent containing 10% acetonitrile as mobile phase. Besides the neurotransmitters DA, NA, and 5-HT, the precursors tyrosine (Tyr) and tryptophan (Trp) as well as the metabolites dehydroxyphenylacetic acid (DOPAC), 4-hydroxy-3-methoxy-phenylglycol (MHPG), and 5-hydroxy-indol-acetic acid (5-HIAA) were quantified in each sample. Quantification was done by peak height evaluation or by area integration using Chromeleon software version 6.08 from Dionex (Sunnyvale, CA, United States).</p>
</sec>
<sec>
<title>Statistical Analysis</title>
<p>Distance traveled in the open field was analyzed using analyses of variance (ANOVAs) for repeated measurements with genotype and sex as between-subject factors and test day or test minute as within-subject factor. Comparison between test days for individual genotypes was performed by calculating paired samples <italic>t</italic>-tests. Neurotransmitter concentrations were analyzed using one-way ANOVAs with genotype as between-subject factor. For each neurotransmitter, values that were smaller than the lower quartile minus three times the interquartile range or larger than the upper quartile plus three times the interquartile range were considered as outliers and excluded from analysis. When appropriate, ANOVAs were followed by LSD <italic>post hoc</italic> analysis for comparing genotypes. A <italic>p</italic>-value of &lt; 0.050 was considered statistically significant.</p>
</sec>
</sec>
<sec>
<title>Results</title>
<sec>
<title>AMPH-Induced Hyperactivity</title>
<p>AMPH administration induced hyperactivity in juvenile mice (<italic>F</italic><sub>2,90</sub> = 20.840, <italic>p</italic> &lt; 0.001), as evidenced by representative locomotor activity patterns in response to AMPH on test day 3 in comparison to saline on day 2 (Figure <xref ref-type="fig" rid="F1">1A</xref>). Importantly, there was also an overall effect of genotype (<italic>F</italic><sub>2,45</sub> = 4.766, <italic>p</italic> = 0.013; day × genotype: <italic>F</italic><sub>4,90</sub> = 0.775, <italic>p</italic> = 0.545), but no general sex effect and no sex interaction with AMPH treatment (<italic>F</italic><sub>1,45</sub> = 0.139, <italic>p</italic> = 0.711; sex × genotype: <italic>F</italic><sub>2,45</sub> = 0.032, <italic>p</italic> = 0.968; day × sex: <italic>F</italic><sub>2,90</sub> = 0.198, <italic>p</italic> = 0.821; day × sex × genotype: <italic>F</italic><sub>4,90</sub> = 0.428, <italic>p</italic> = 0.788). A comparison between test days revealed that the distanced traveled following AMPH treatment was clearly higher than the day before in response to saline (<italic>p</italic> &lt; 0.001; Figure <xref ref-type="fig" rid="F1">1B</xref>). This difference held true for individual genotypes (<italic>Shank1<sup>+/+</sup></italic>: <italic>t</italic><sub>14</sub> = 3.787, <italic>p</italic> = 0.001, one-tailed; <italic>Shank1<sup>+/-</sup></italic>: <italic>t</italic><sub>19</sub> = 2.953, <italic>p</italic> = 0.008; <italic>Shank1<sup>-/-</sup></italic>: <italic>t</italic><sub>15</sub> = 2.495, <italic>p</italic> = 0.025; Figure <xref ref-type="fig" rid="F1">1B</xref>′). When comparing locomotor activity between individual genotypes separately for each test day, evidence for genotype-dependent differences in the distance traveled was obtained under baseline conditions (<italic>F</italic><sub>2,48</sub> = 6.619, <italic>p</italic> = 0.003; Figure <xref ref-type="fig" rid="F2">2A</xref>) and in response to saline (<italic>F</italic><sub>2,48</sub> = 5.076, <italic>p</italic> = 0.010; Figure <xref ref-type="fig" rid="F2">2B</xref>). Specifically, on day 1, <italic>Shank1<sup>+/+</sup></italic> mice displayed slightly higher levels of locomotor activity than <italic>Shank1<sup>-/-</sup></italic> mice (<italic>p</italic> = 0.001) but did not differ significantly from <italic>Shank1<sup>+/-</sup></italic> mice (<italic>p</italic> = 0.059). Similarly, on day 2, <italic>Shank1<sup>+/+</sup></italic> mice engaged more in locomotor activity than <italic>Shank1<sup>-/-</sup></italic> (<italic>p</italic> = 0.004) and <italic>Shank1<sup>+/-</sup></italic> mice (<italic>p</italic> = 0.019). Locomotor activity displayed by <italic>Shank1<sup>+/-</sup></italic> and <italic>Shank1<sup>-/-</sup></italic> mice did not differ from each other under baseline conditions (<italic>p</italic> = 0.059) and in response to saline (<italic>p</italic> = 0.428). Although there was only a trend for a genotype effect on AMPH-induced hyperactivity on the third test day and the overall level of locomotor activity was not significantly affected by <italic>Shank1</italic> deletion (<italic>F</italic><sub>2,48</sub> = 2.602, <italic>p</italic> = 0.085), the temporal response pattern differed between genotypes (genotype: <italic>F</italic><sub>2,45</sub> = 2.186, <italic>p</italic> = 0.124; time × genotype: <italic>F</italic><sub>88,1980</sub> = 1.278, <italic>p</italic> = 0.045; Figure <xref ref-type="fig" rid="F2">2C</xref>). After about 10 min with similar locomotor activity levels in all genotypes, <italic>Shank1<sup>+/+</sup></italic> mice displayed a strong increase in locomotor activity and maintained high activity levels for about 30 min, whereas the AMPH-induced increase was less prominent in <italic>Shank1<sup>+/-</sup></italic> and <italic>Shank1<sup>-/-</sup></italic> mice (Figures <xref ref-type="fig" rid="F2">2A′–C′</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>AMPH-induced hyperactivity in juvenile <italic>Shank1</italic> mice. <bold>(A)</bold> Exemplary figure depicting the locomotor activity pattern of individual juvenile <italic>Shank1<sup>+/+</sup>, Shank1<sup>+/-</sup></italic>, and <italic>Shank1<sup>-/-</sup></italic> mice injected with saline (NaCl) on day 2 (upper panel) and with AMPH on day 3 (lower panel); measured over 45 min. <bold>(B)</bold> Bar graph depicting the distance traveled by all genotypes during baseline testing (white bar), following saline administration (blue bar), and after AMPH treatment (green bar). <bold>(B′)</bold> Line graph depicting the distance traveled by <italic>Shank1<sup>+/+</sup></italic> (black circle), <italic>Shank1<sup>+/-</sup></italic> (white circle), and <italic>Shank1<sup>-/-</sup></italic> (black triangle) over the three consecutive test days. Data are presented as means + SEM or means ± SEM. <sup>##</sup><italic>p</italic> &lt; 0.001 <bold>(B)</bold>, <sup>#</sup><italic>p</italic> &lt; 0.05 vs. day 2 <bold>(B′)</bold>.</p>
</caption>
<graphic xlink:href="fnmol-11-00419-g001"></graphic>
</fig>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>AMPH-induced hyperactivity in juvenile <italic>Shank1</italic> mice. <bold>(A–C)</bold> Bar graphs and <bold>(A′–C′)</bold> line graphs depicting the distance traveled by <italic>Shank1<sup>+/+</sup></italic> (black bar/black circle), <italic>Shank1<sup>+/-</sup></italic> (striped bar/white circle), and <italic>Shank1<sup>-/-</sup></italic> (white bar/black triangle). Locomotor activity was compared during baseline testing <bold>(A,A′)</bold>, following saline administration <bold>(B,B′)</bold>, and after AMPH treatment <bold>(C,C′)</bold>. Data are presented as means + SEM or means ± SEM. <sup>∗</sup><italic>p</italic> &lt; 0.05, <sup>∗∗</sup><italic>p</italic> &lt; 0.001.</p>
</caption>
<graphic xlink:href="fnmol-11-00419-g002"></graphic>
</fig>
<p>Of note, the time spent in the center of the open field was also affected and changed across test days (<italic>F</italic><sub>2,90</sub> = 33.804, <italic>p</italic> &lt; 0.001). There were overall effects of genotype (<italic>F</italic><sub>2,45</sub> = 9.573, <italic>p</italic> &lt; 0.001; day × genotype: <italic>F</italic><sub>4,90</sub> = 2.774, <italic>p</italic> = 0.032) and sex (<italic>F</italic><sub>1,45</sub> = 7.393, <italic>p</italic> = 0.009; sex × genotype: <italic>F</italic><sub>2,45</sub> = 0.091, <italic>p</italic> = 0.914), but no sex interaction with AMPH treatment (day × sex: <italic>F</italic><sub>2,90</sub> = 0.352, <italic>p</italic> = 0.704; day × sex × genotype: <italic>F</italic><sub>4,90</sub> = 0.188, <italic>p</italic> = 0.944). When comparing the time spent in the center between individual genotypes separately for each test day, prominent genotype differences were detected across all three test days. Specifically, under baseline conditions, genotypes differed from each other (<italic>F</italic><sub>2,48</sub> = 9.360, <italic>p</italic> &lt; 0.001; Supplementary Figure <xref ref-type="supplementary-material" rid="SM1">1A</xref>) and <italic>Shank1<sup>+/+</sup></italic> mice spent more time in the center than <italic>Shank1<sup>+/-</sup></italic> (<italic>p</italic> = 0.018) and <italic>Shank1<sup>-/-</sup></italic> mice (<italic>p</italic> &lt; 0.001), with the latter also differing from each other (<italic>p</italic> = 0.037). Similarly, center time differed between genotypes in response to saline on day 2 (<italic>F</italic><sub>2,48</sub> = 4.388, <italic>p</italic> = 0.018; Supplementary Figure <xref ref-type="supplementary-material" rid="SM1">1B</xref>), with <italic>Shank1<sup>+/+</sup></italic> mice again spending more time in the center than <italic>Shank1<sup>+/-</sup></italic> (<italic>p</italic> = 0.015) and <italic>Shank1<sup>-/-</sup></italic> mice (<italic>p</italic> = 0.010), but the latter not differing from each other (<italic>p</italic> = 0.774). A similar pattern was obtained also in response to AMPH on day 3 (<italic>F</italic><sub>2,48</sub> = 5.367, <italic>p</italic> = 0.008; Supplementary Figure <xref ref-type="supplementary-material" rid="SM1">1C</xref>), with <italic>Shank1<sup>+/+</sup></italic> mice spending more time in the center than <italic>Shank1<sup>+/-</sup></italic> (<italic>p</italic> = 0.011) and <italic>Shank1<sup>-/-</sup></italic> mice (<italic>p</italic> = 0.004), but the latter not differing from each other (<italic>p</italic> = 0.546).</p>
<p>Consistent with the data obtained in juveniles, AMPH administration induced hyperactivity in adult mice (<italic>F</italic><sub>2,148</sub> = 107.888, <italic>p</italic> &lt; 0.001), and this is similarly evidenced by representative locomotor activity patterns on test day 3 in comparison to saline on day 2 (Figure <xref ref-type="fig" rid="F3">3A</xref>). Again, there was a general genotype effect (<italic>F</italic><sub>2,74</sub> = 10.233, <italic>p</italic> &lt; 0.001), while sex had no prominent impact and did not modulate AMPH effects in a genotype-dependent manner (<italic>F</italic><sub>1,74</sub> = 3.358, <italic>p</italic> = 0.064; sex × genotype: <italic>F</italic><sub>2,74</sub> = 0.349, <italic>p</italic> = 0.707; day × sex: <italic>F</italic><sub>2,148</sub> = 3.324, <italic>p</italic> = 0.039; day × sex × genotype: <italic>F</italic><sub>4,148</sub> = 0.957, <italic>p</italic> = 0.433). This was further supported by a comparison between test days that revealed clearly higher levels of locomotor activity following AMPH treatment than the day before in response to saline (<italic>p</italic> &lt; 0.001; Figure <xref ref-type="fig" rid="F3">3B</xref>) and this difference held true for individual genotypes (<italic>Shank1<sup>+/+</sup></italic>: <italic>t</italic><sub>23</sub> = 5.800, <italic>p</italic> &lt; 0.001, one-tailed; <italic>Shank1<sup>+/-</sup></italic>: <italic>t</italic><sub>27</sub> = 8.478, <italic>p</italic> &lt; 0.001; <italic>Shank1<sup>-/-</sup></italic>: <italic>t</italic><sub>27</sub> = 5.123, <italic>p</italic> &lt; 0.001; Figure <xref ref-type="fig" rid="F3">3B</xref>′). Despite this general effect, however, AMPH responsivity in adult mice was strongly affected by <italic>Shank1</italic> deletion (day × genotype: <italic>F</italic><sub>4,148</sub> = 10.030, <italic>p</italic> &lt; 0.001). While locomotor activity did not differ between genotypes under baseline conditions (<italic>F</italic><sub>2,77</sub> = 0.980, <italic>p</italic> = 0.380; Figure <xref ref-type="fig" rid="F4">4A</xref>) and no differences were evident in response to saline (<italic>F</italic><sub>2,77</sub> = 0.801, <italic>p</italic> = 0.453; Figure <xref ref-type="fig" rid="F4">4B</xref>), prominent genotype differences were evident following AMPH treatment. In contrast to juvenile mice, AMPH-induced hyperactivity was clearly dependent on genotype in adult mice (<italic>F</italic><sub>2,77</sub> = 10.449, <italic>p</italic> &lt; 0.001). Specifically, in comparison to <italic>Shank1<sup>-/-</sup></italic> mice, there was increased hyperactivity in <italic>Shank1<sup>+/+</sup></italic> (<italic>p</italic> &lt; 0.001) and <italic>Shank1<sup>+/-</sup></italic> mice (<italic>p</italic> &lt; 0.001) following AMPH treatment, whereas AMPH-induced hyperactivity did not differ between <italic>Shank1<sup>+/+</sup></italic> and <italic>Shank1<sup>+/-</sup></italic> mice (<italic>p</italic> = 0.768). This prominent genotype effect was also reflected in the temporal response pattern (genotype: <italic>F</italic><sub>2,77</sub> = 10.449, <italic>p</italic> &lt; 0.001; time × genotype: <italic>F</italic><sub>88,3388</sub> = 6.004, <italic>p</italic> &lt; 0.001; Figure <xref ref-type="fig" rid="F4">4C</xref>). After about 10 min with similar locomotor activity levels in all genotypes, <italic>Shank1<sup>+/+</sup></italic> and <italic>Shank1<sup>+/-</sup></italic> mice displayed a strong increase in locomotor activity and maintained high activity levels until the end of testing, whereas the AMPH-induced increase was very mild in <italic>Shank1<sup>-/-</sup></italic> mice (Figures <xref ref-type="fig" rid="F4">4A′–C′</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p><bold>(A)</bold> AMPH-induced hyperactivity in adult <italic>Shank1</italic> mice. Exemplary figure depicting the locomotor activity pattern of individual adult <italic>Shank1<sup>+/+</sup>, Shank1<sup>+/-</sup></italic>, and <italic>Shank1<sup>-/-</sup></italic> mice injected with saline (NaCl) on day 2 (upper panel) and with AMPH on day 3 (lower panel); measured over 45 min. <bold>(B)</bold> Bar graph depicting the distance traveled by all genotypes during baseline testing (white bar), following saline administration (blue bar), and after AMPH treatment (green bar). <bold>(B′)</bold> Line graph depicting the distance traveled by <italic>Shank1<sup>+/+</sup></italic> (black circle), <italic>Shank1<sup>+/-</sup></italic> (white circle), and <italic>Shank1<sup>-/-</sup></italic> (black triangle) over the three consecutive test days. Data are presented as means + SEM or means ± SEM. <sup>##</sup><italic>p</italic> &lt; 0.001 <bold>(B)</bold>, <sup>##</sup><italic>p</italic> &lt; 0.001 vs. day 2 <bold>(B′)</bold>.</p>
</caption>
<graphic xlink:href="fnmol-11-00419-g003"></graphic>
</fig>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>AMPH-induced hyperactivity in adult <italic>Shank1</italic> mice. <bold>(A–C)</bold> Bar graphs and <bold>(A′–C′)</bold> line graphs depicting the distance traveled by <italic>Shank1<sup>+/+</sup></italic> (black bar/black circle), <italic>Shank1<sup>+/-</sup></italic> (striped bar/white circle), and <italic>Shank1<sup>-/-</sup></italic> (white bar/black triangle). Locomotor activity was compared during baseline testing <bold>(A,A′)</bold>, following saline administration <bold>(B,B′)</bold>, and after AMPH treatment <bold>(C,C′)</bold>. Data are presented as means + SEM or means ± SEM. <sup>∗∗</sup><italic>p</italic> &lt; 0.001.</p>
</caption>
<graphic xlink:href="fnmol-11-00419-g004"></graphic>
</fig>
<p>Because <italic>Shank1</italic> deletion had prominent effects on the induction of locomotor activity following AMPH treatment in <italic>Shank1<sup>-/-</sup></italic> mice but not <italic>Shank1<sup>+/-</sup></italic> mice, we also tested whether rearing behavior was affected by genotype in a similar manner in adult mice. AMPH administration induced rearing behavior (<italic>F</italic><sub>2,148</sub> = 3.885, <italic>p</italic> = 0.023) and, alike locomotor activity, there was a general genotype effect on rearing behavior (<italic>F</italic><sub>2,74</sub> = 7.794, <italic>p</italic> &lt; 0.001). Sex had no prominent impact and did not modulate AMPH effects (<italic>F</italic><sub>1,74</sub> = 0.179, <italic>p</italic> = 0.674; sex × genotype: <italic>F</italic><sub>2,74</sub> = 0.578, <italic>p</italic> = 0.536; day × sex: <italic>F</italic><sub>4,148</sub> = 0.544, <italic>p</italic> = 0.582; day × sex × genotype: <italic>F</italic><sub>4,148</sub> = 1.815, <italic>p</italic> = 0.129). Importantly, however, AMPH responsivity was again strongly affected by <italic>Shank1</italic> deletion (day × genotype: <italic>F</italic><sub>4,148</sub> = 2.926, <italic>p</italic> = 0.023). While rearing behavior did not differ between genotypes under baseline conditions (<italic>F</italic><sub>2,77</sub> = 1.163, <italic>p</italic> = 0.318; Supplementary Figure <xref ref-type="supplementary-material" rid="SM2">2A</xref>) and no differences were evident in response to saline (<italic>F</italic><sub>2,77</sub> = 1.406, <italic>p</italic> = 0.251; Supplementary Figure <xref ref-type="supplementary-material" rid="SM2">2B</xref>), prominent genotype differences were evident following AMPH treatment (<italic>F</italic><sub>2,77</sub> = 8.629, <italic>p</italic> &lt; 0.001). Specifically, in comparison to <italic>Shank1<sup>+/+</sup></italic> mice, there was reduced rearing behavior in <italic>Shank1<sup>+/-</sup></italic> (<italic>p</italic> &lt; 0.001) and <italic>Shank1<sup>-/-</sup></italic> mice (<italic>p</italic> &lt; 0.001) following AMPH treatment, whereas AMPH-induced rearing behavior did not differ between <italic>Shank1<sup>+/-</sup></italic> and <italic>Shank1<sup>-/-</sup></italic> mice (<italic>p</italic> = 0.788). This prominent genotype effect was also reflected in the temporal response pattern (genotype: <italic>F</italic><sub>2,77</sub> = 8.629, <italic>p</italic> &lt; 0.001; time × genotype: <italic>F</italic><sub>88,3388</sub> = 2.040, <italic>p</italic> &lt; 0.001; Supplementary Figure <xref ref-type="supplementary-material" rid="SM2">2C</xref>). After about 10 min with similar levels of rearing behavior in all genotypes, only <italic>Shank1<sup>+/+</sup></italic> mice displayed a strong increase in rearing behavior and maintained high rearing levels until the end of testing, whereas the AMPH-induced increase was very mild in <italic>Shank1<sup>+/-</sup></italic> and <italic>Shank1<sup>-/-</sup></italic> mice (Supplementary Figures <xref ref-type="supplementary-material" rid="SM2">2A′–C′</xref>).</p>
<p>Of note, the time spent in the center of the open field was also affected and changed across test days (<italic>F</italic><sub>2,148</sub> = 30.879, <italic>p</italic> &lt; 0.001), but no genotype-dependent differences were obtained (<italic>F</italic><sub>2,74</sub> = 0.998, <italic>p</italic> = 0.373; day × genotype: <italic>F</italic><sub>4,148</sub> = 1.579, <italic>p</italic> = 0.183), with sex having also no impact (<italic>F</italic><sub>1,74</sub> = 0.270, <italic>p</italic> = 0.605; sex × genotype: <italic>F</italic><sub>2,74</sub> = 0.138, <italic>p</italic> = 0.871; day × sex: <italic>F</italic><sub>2,148</sub> = 1.543, <italic>p</italic> = 0.217; day × sex × genotype: <italic>F</italic><sub>4,148</sub> = 0.660, <italic>p</italic> = 0.621). When comparing genotypes on individual test days, no differences were observed under baseline conditions (<italic>F</italic><sub>2,77</sub> = 0.573, <italic>p</italic> = 0.566; Supplementary Figure <xref ref-type="supplementary-material" rid="SM3">3A</xref>) and in response to saline on day 2 (<italic>F</italic><sub>2,77</sub> = 2.590, <italic>p</italic> = 0.082; Supplementary Figure <xref ref-type="supplementary-material" rid="SM3">3B</xref>), whereas genotypes differed from each other in response to AMPH on day 3 (<italic>F</italic><sub>2,77</sub> = 4.318, <italic>p</italic> = 0.017; Supplementary Figure <xref ref-type="supplementary-material" rid="SM3">3C</xref>). Specifically, <italic>Shank1<sup>+/-</sup></italic> mice spent less time in the center than <italic>Shank1<sup>+/+</sup></italic> mice (<italic>p</italic> = 0.005) but not than <italic>Shank1<sup>-/-</sup></italic> mice (<italic>p</italic> = 0.055), with the latter also not differing from each other (<italic>p</italic> = 0.324).</p>
</sec>
<sec>
<title>MDMA-Induced Hyperactivity</title>
<p>MDMA administration induced hyperactivity in adult mice (<italic>F</italic><sub>2,82</sub> = 9.290, <italic>p</italic> &lt; 0.001), as again evidenced by representative locomotor activity patterns in response to MDMA on test day 3 in comparison to saline on day 2 (Figure <xref ref-type="fig" rid="F5">5A</xref>). Consistent with AMPH, there was a general genotype effect (<italic>F</italic><sub>2,41</sub> = 13.153, <italic>p</italic> &lt; 0.001), with sex having no prominent impact in modulating MDMA effects (<italic>F</italic><sub>1,41</sub> = 0.689, <italic>p</italic> = 0.411; sex × genotype: <italic>F</italic><sub>2,41</sub> = 4.155, <italic>p</italic> = 0.023; day × sex: <italic>F</italic><sub>2,82</sub> = 2.487, <italic>p</italic> = 0.089; day × sex × genotype: <italic>F</italic><sub>4,82</sub> = 0.534, <italic>p</italic> = 0.711). Again, this was further supported by a comparison between test days that revealed clearly higher levels of locomotor activity following MDMA treatment than the day before in response to saline (<italic>p</italic> = 0.003; Figure <xref ref-type="fig" rid="F5">5B</xref>). However, despite this difference held true for <italic>Shank1<sup>+/+</sup></italic> (<italic>t</italic><sub>13</sub> = 2.000, <italic>p</italic> = 0.034, one-tailed) and <italic>Shank1<sup>+/-</sup></italic> mice (<italic>t</italic><sub>18</sub> = 3.356, <italic>p</italic> = 0.004), no evidence for MDMA-induced hyperactivity was evident in <italic>Shank1<sup>-/-</sup></italic> mice, with their level of locomotor activity being the same following MDMA as in response to saline (<italic>t</italic><sub>13</sub> = 1.188, <italic>p</italic> = 0.256; Figure <xref ref-type="fig" rid="F5">5B′</xref>). In fact, similar to AMPH, although more prominent, MDMA responsivity in adult mice was strongly affected by <italic>Shank1</italic> deletion (day × genotype: <italic>F</italic><sub>4,82</sub> = 2.759, <italic>p</italic> = 0.033) and clear genotype differences in hyperactivity following MDMA administration were evident (<italic>F</italic><sub>2,44</sub> = 6.606, <italic>p</italic> = 0.003). Importantly, the lack of MDMA-induced hyperactivity in <italic>Shank1<sup>-/-</sup></italic> mice was not driven by baseline differences in locomotor activity. Although genotype differences were evident under baseline conditions (<italic>F</italic><sub>2,44</sub> = 8.286, <italic>p</italic> = 0.001; Figure <xref ref-type="fig" rid="F6">6A</xref>) and <italic>Shank1<sup>-/-</sup></italic> mice displayed lower locomotor activity compared to <italic>Shank1<sup>+/+</sup></italic> (<italic>p</italic> &lt; 0.001) and <italic>Shank1<sup>+/-</sup></italic> mice (<italic>p</italic> = 0.040), with the latter also differing from each other (<italic>p</italic> = 0.029), locomotor activity did not differ between genotypes in response to saline (<italic>F</italic><sub>2,44</sub> = 2.445, <italic>p</italic> = 0.098; Figure <xref ref-type="fig" rid="F6">6B</xref>). Specifically, as compared to <italic>Shank1<sup>-/-</sup></italic> mice, increased MDMA-induced hyperactivity was detected in <italic>Shank1<sup>+/+</sup></italic> (<italic>p</italic> = 0.002) and <italic>Shank1<sup>+/-</sup></italic> mice (<italic>p</italic> = 0.004), whereas the latter two did not differ from each other (<italic>p</italic> = 0.652). This prominent genotype effect was also reflected in the temporal response pattern (genotype: <italic>F</italic><sub>2,44</sub> = 6.606, <italic>p</italic> = 0.003; time × genotype: <italic>F</italic><sub>88,1936</sub> = 0.999, <italic>p</italic> = 0.484; Figure <xref ref-type="fig" rid="F6">6C</xref>). While locomotor activity levels increased in <italic>Shank1<sup>+/+</sup></italic> and <italic>Shank1<sup>+/-</sup></italic> mice already from the very beginning of testing, MDMA treatment in <italic>Shank1<sup>-/-</sup></italic> mice was associated with a decrease of locomotor activity, with very low activity levels being maintained in <italic>Shank1<sup>-/-</sup></italic> mice throughout testing (Figures <xref ref-type="fig" rid="F6">6A′–C′</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>MDMA-induced hyperactivity in adult <italic>Shank1</italic> mice. <bold>(A)</bold> Exemplary figure depicting the locomotor activity pattern of individual adult <italic>Shank1<sup>+/+</sup>, Shank1<sup>+/-</sup></italic>, and <italic>Shank1<sup>-/-</sup></italic> mice injected with saline (NaCl) on day 2 (upper panel) and with MDMA on day 3 (lower panel); measured over 45 min. <bold>(B)</bold> Bar graph depicting the distance traveled by all genotypes during baseline testing (white bar), following saline administration (blue bar), and after MDMA treatment (orange bar). <bold>(B′)</bold> Line graph depicting the distance traveled by <italic>Shank1<sup>+/+</sup></italic> (black circle), <italic>Shank1<sup>+/-</sup></italic> (white circle), and <italic>Shank1<sup>-/-</sup></italic> (black triangle) over the three consecutive test days. Data are presented as means + SEM or means ± SEM. <sup>#</sup><italic>p</italic> &lt; 0.05, <sup>##</sup><italic>p</italic> &lt; 0.001 <bold>(B)</bold>, <sup>#</sup><italic>p</italic> &lt; 0.05 vs. day 2 <bold>(B′)</bold>.</p>
</caption>
<graphic xlink:href="fnmol-11-00419-g005"></graphic>
</fig>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>MDMA-induced hyperactivity in adult <italic>Shank1</italic> mice. <bold>(A–C)</bold> Bar graphs and <bold>(A′–C′)</bold> line graphs depicting the distance traveled by <italic>Shank1<sup>+/+</sup></italic> (black bar/black circle), <italic>Shank1<sup>+/-</sup></italic> (striped bar/white circle), and <italic>Shank1<sup>-/-</sup></italic> (white bar/black triangle). Locomotor activity was compared during baseline testing <bold>(A,A′)</bold>, following saline administration <bold>(B,B′)</bold>, and after MDMA treatment <bold>(C,C′)</bold>. Data are presented as means + SEM or means ± SEM. <sup>∗</sup><italic>p</italic> &lt; 0.05, <sup>∗∗</sup><italic>p</italic> &lt; 0.001.</p>
</caption>
<graphic xlink:href="fnmol-11-00419-g006"></graphic>
</fig>
<p>Of note, the time spent in the center of the open field was also affected and changed across test days (<italic>F</italic><sub>2,82</sub> = 43.972, <italic>p</italic> &lt; 0.001), and genotype-dependent differences were obtained (<italic>F</italic><sub>2,41</sub> = 5.374, <italic>p</italic> = 0.008; day × genotype: <italic>F</italic><sub>4,82</sub> = 3.264, <italic>p</italic> = 0.016), with sex having no impact (<italic>F</italic><sub>1,41</sub> = 0.001, <italic>p</italic> = 0.978; sex × genotype: <italic>F</italic><sub>2,41</sub> = 0.823, <italic>p</italic> = 0.446 day × sex: <italic>F</italic><sub>2,82</sub> = 0.061, <italic>p</italic> = 0.941; day × sex × genotype: <italic>F</italic><sub>4,82</sub> = 0.148, <italic>p</italic> = 0.963). When comparing genotypes on individual test days, genotype differences were evident under baseline conditions (<italic>F</italic><sub>2,44</sub> = 5.505, <italic>p</italic> = 0.007; Supplementary Figure <xref ref-type="supplementary-material" rid="SM4">4A</xref>). Specifically, <italic>Shank1<sup>+/+</sup></italic> mice spent more time in the center than <italic>Shank1<sup>+/-</sup></italic> (<italic>p</italic> = 0.005) and <italic>Shank1<sup>-/-</sup></italic> mice (<italic>p</italic> = 0.006), with the latter not differing from each other (<italic>p</italic> = 0.883). Genotypes did not differ from each other in terms of the time spent in the center on day 2 in response to saline (<italic>F</italic><sub>2,44</sub> = 1.537, <italic>p</italic> = 0.226; Supplementary Figure <xref ref-type="supplementary-material" rid="SM4">4B</xref>), and on day 3 in response to MDMA (<italic>F</italic><sub>2,44</sub> = 1.170, <italic>p</italic> = 0.320; Supplementary Figure <xref ref-type="supplementary-material" rid="SM4">4C</xref>).</p>
<p>Because MDMA-induced hyperactivity was completely absent in <italic>Shank1<sup>-/-</sup></italic> mice, we also tested the hypothesis that MDMA treatment might have induced repetitive and stereotyped movement patterns, such as circling behavior (<xref ref-type="bibr" rid="B74">Powell et al., 2004</xref>; <xref ref-type="bibr" rid="B78">Risbrough et al., 2006</xref>). In fact, there was an overall increase in repetitive circling behavior following MDMA treatment (<italic>F</italic><sub>1,41</sub> = 78.866, <italic>p</italic> &lt; 0.001). Importantly, however, the increase in circling occurred irrespective of genotype and can thus not explain the lack of MDMA-induced hyperactivity in <italic>Shank1<sup>-/-</sup></italic> mice. Specifically, there was no prominent effect of genotype (<italic>F</italic><sub>2,41</sub> = 1.925, <italic>p</italic> = 0.159; day × genotype: <italic>F</italic><sub>2,41</sub> = 1.678, <italic>p</italic> = 0.199) or sex (<italic>F</italic><sub>1,41</sub> = 0.004, <italic>p</italic> = 0.953; sex × genotype: <italic>F</italic><sub>2,41</sub> = 1.171, <italic>p</italic> = 0.320; day × sex: <italic>F</italic><sub>1,41</sub> = 0.061, <italic>p</italic> = 0.806; day × sex × genotype: <italic>F</italic><sub>2,41</sub> = 1.695, <italic>p</italic> = 0.196). A comparison between test days revealed that circling behavior following MDMA treatment was clearly higher than the day before in response to saline (<italic>p</italic> &lt; 0.001; Supplementary Figure <xref ref-type="supplementary-material" rid="SM5">5A</xref>), yet this increase occurred irrespective of genotype and held true for all individual genotypes (<italic>Shank1<sup>+/+</sup></italic>: <italic>t</italic><sub>13</sub> = 4.283, <italic>p</italic> &lt; 0.001, one-tailed; <italic>Shank1<sup>+/-</sup></italic>: <italic>t</italic><sub>18</sub> = 7.681, <italic>p</italic> &lt; 0.001; <italic>Shank1<sup>-/-</sup></italic>: <italic>t</italic><sub>27</sub> = 4.065, <italic>p</italic> = 0.001; Supplementary Figure <xref ref-type="supplementary-material" rid="SM5">5A</xref>′).</p>
</sec>
<sec>
<title>Neurotransmitter Measurements</title>
<sec>
<title>Prefrontal Cortex</title>
<p>Concentrations of the DA precursor Tyr in the prefrontal cortex did not differ between genotypes (<italic>F</italic><sub>2,39</sub> = 0.364, <italic>p</italic> = 0.697; Figure <xref ref-type="fig" rid="F7">7A</xref>). <italic>Shank1</italic> deletion, however, affected the level of the 5-HT precursor Trp (<italic>F</italic><sub>2,40</sub> = 3.933, <italic>p</italic> = 0.028; Figure <xref ref-type="fig" rid="F7">7B</xref>). Specifically, <italic>Shank1<sup>-/-</sup></italic> mice had higher Trp concentrations in the prefrontal cortex than <italic>Shank1<sup>+/+</sup></italic> (<italic>p</italic> = 0.019) and <italic>Shank1<sup>+/-</sup></italic> mice (<italic>p</italic> = 0.018), with the latter two not differing from each other (<italic>p</italic> = 0.910).</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Catecholamine/indolamine, precursor, and metabolite concentrations in the prefrontal cortex of <italic>Shank1</italic> mice. Basal levels of <bold>(A)</bold> Tyrosine (Tyr), <bold>(B)</bold> Tryptophan (Trp), <bold>(C)</bold> Dopamine (DA), <bold>(D)</bold> DA-metabolite dehydroxyphenylacetic acid (DOPAC), <bold>(E)</bold> DOPAC/DA ratio, <bold>(F)</bold> Noradrenaline (NA), <bold>(G)</bold> NA-metabolite 4-hydroxy-3-methoxy-phenylglycol (MHPG), <bold>(H)</bold> MHPG/NA ratio, <bold>(I)</bold> 5-hydroxytryptamine (5-HT; serotonin), <bold>(J)</bold> 5-HT-metabolite 5-hydroxy-indol-acetic acid (5-HIAA), and <bold>(K)</bold> 5-HIAA/5-HT ratio in <italic>Shank1<sup>+/+</sup></italic> (black bar), <italic>Shank1<sup>+/-</sup></italic> (striped bar), and <italic>Shank1<sup>-/-</sup></italic> mice (white bar). <italic>N</italic> = 10–16 per genotype. Data are presented as means + SEM. <sup>∗</sup><italic>p</italic> &lt; 0.05. Schematic representation of the prefrontal cortex was adapted from <xref ref-type="bibr" rid="B68">Paxinos and Franklin (2001)</xref>.</p>
</caption>
<graphic xlink:href="fnmol-11-00419-g007"></graphic>
</fig>
<p>Although basal DA levels clearly tended to be lower in <italic>Shank1<sup>-/-</sup></italic> mice, apparent genotype differences in DA levels did not reach statistical significance (<italic>F</italic><sub>2,38</sub> = 3.192, <italic>p</italic> = 0.052; Figure <xref ref-type="fig" rid="F7">7C</xref>), while the concentration of the DA metabolite DOPAC differed between genotypes (<italic>F</italic><sub>2,40</sub> = 3.879, <italic>p</italic> = 0.029; Figure <xref ref-type="fig" rid="F7">7D</xref>). <italic>Shank1<sup>+/+</sup></italic> mice had higher DOPAC concentrations than <italic>Shank1<sup>-/-</sup></italic> (<italic>p</italic> = 0.008) but not <italic>Shank1<sup>+/-</sup></italic> mice (<italic>p</italic> = 0.290), with <italic>Shank1<sup>-/-</sup></italic> and <italic>Shank1<sup>+/-</sup></italic> mice also not differing from each other (<italic>p</italic> = 0.102). The DOPAC/DA ratio, however, was not affected by <italic>Shank1</italic> deletion (<italic>F</italic><sub>2,38</sub> = 0.261, <italic>p</italic> = 0.772; Figure <xref ref-type="fig" rid="F7">7E</xref>).</p>
<p>While DA levels were not significantly affected by genotype, <italic>Shank1</italic> deletion affected basal NA concentrations (<italic>F</italic><sub>2,35</sub> = 6.597, <italic>p</italic> = 0.004; Figure <xref ref-type="fig" rid="F7">7F</xref>). <italic>Shank1<sup>-/-</sup></italic> mice had higher concentrations of NA as compared to <italic>Shank1<sup>+/+</sup></italic> (<italic>p</italic> = 0.003) and <italic>Shank1<sup>+/-</sup></italic> mice (<italic>p</italic> = 0.003), while <italic>Shank1<sup>+/+</sup></italic> and <italic>Shank1<sup>+/-</sup></italic> mice did not differ in that aspect (<italic>p</italic> = 0.797). There were no differences between genotypes in the concentrations of the NA metabolite MHPG (<italic>F</italic><sub>2,39</sub> = 1.604, <italic>p</italic> = 0.214; Figure <xref ref-type="fig" rid="F7">7G</xref>), yet the MHPG/NA ratio differed between genotypes (<italic>F</italic><sub>2,34</sub> = 4.066, <italic>p</italic> = 0.026; Figure <xref ref-type="fig" rid="F7">7H</xref>). The MHPG/NA ratio was lower in <italic>Shank1<sup>-/-</sup></italic> mice as compared to <italic>Shank1<sup>+/-</sup></italic> mice (<italic>p</italic> = 0.007) but not as compared to <italic>Shank1<sup>+/+</sup></italic> mice (<italic>p</italic> = 0.140). No significant differences in MHPG/NA ratio between <italic>Shank1<sup>+/+</sup></italic> and <italic>Shank1<sup>+/-</sup></italic> mice were detected (<italic>p</italic> = 0.114).</p>
<p>The 5-HT system was not affected by <italic>Shank1</italic> deletion. Specifically, basal 5-HT concentrations, the levels of the main 5-HT metabolite 5-HIAA, and the 5-HIAA/5-HT ratio did not differ between genotypes (all <italic>p</italic>-values &gt; 0.100; Figures <xref ref-type="fig" rid="F7">7I</xref>–<xref ref-type="fig" rid="F7">K</xref>).</p>
</sec>
<sec>
<title>Nucleus Accumbens</title>
<p>In the nucleus accumbens, <italic>Shank1</italic> deletion affected the concentration of the DA precursor Tyr (<italic>F</italic><sub>2,40</sub> = 3.421, <italic>p</italic> = 0.043; Figure <xref ref-type="fig" rid="F8">8A</xref>) and the 5-HT precursor Trp (<italic>F</italic><sub>2,40</sub> = 3.709, <italic>p</italic> = 0.033; Figure <xref ref-type="fig" rid="F8">8B</xref>). Specifically, <italic>Shank1<sup>-/-</sup></italic> mice had higher Tyr concentrations than <italic>Shank1<sup>+/+</sup></italic> mice (<italic>p</italic> = 0.013) but not <italic>Shank1<sup>+/-</sup></italic> mice (<italic>p</italic> = 0.281), with the latter also not differing from each other (<italic>p</italic> = 0.143). Trp levels in <italic>Shank1<sup>-/-</sup></italic> mice were higher than in <italic>Shank1<sup>+/+</sup></italic> (<italic>p</italic> = 0.018) and <italic>Shank1<sup>+/-</sup></italic> mice (<italic>p</italic> = 0.028), whereas the latter did not differ from each other (<italic>p</italic> = 0.901).</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>Catecholamine/indolamine, precursor, and metabolite concentrations in the nucleus accumbens of <italic>Shank1</italic> mice. Basal levels of <bold>(A)</bold> Tyrosine (Tyr), <bold>(B)</bold> Tryptophan (Trp), <bold>(C)</bold> Dopamine (DA), <bold>(D)</bold> DA-metabolite dehydroxyphenylacetic acid (DOPAC), <bold>(E)</bold> DOPAC/DA ratio, <bold>(F)</bold> Noradrenaline (NA), <bold>(G)</bold> NA-metabolite 4-hydroxy-3-methoxy-phenylglycol (MHPG), <bold>(H)</bold> MHPG/NA ratio, <bold>(I)</bold> 5-hydroxytryptamine (5-HT; serotonin), <bold>(J)</bold> 5-HT-metabolite 5-hydroxy-indol-acetic acid (5-HIAA), and <bold>(K)</bold> 5-HIAA/5-HT ratio in <italic>Shank1<sup>+/+</sup></italic> (black bar), <italic>Shank1<sup>+/-</sup></italic> (striped bar), and <italic>Shank1<sup>-/-</sup></italic> mice (white bar). <italic>N</italic> = 13–16 per genotype. Data are presented as means + SEM. <sup>∗</sup><italic>p</italic> &lt; 0.05. Schematic representation of the nucleus accumbens was adapted from <xref ref-type="bibr" rid="B68">Paxinos and Franklin (2001)</xref>.</p>
</caption>
<graphic xlink:href="fnmol-11-00419-g008"></graphic>
</fig>
<p>However, despite genotype differences in the levels of the precursors, there were no differences between genotypes in DA, DOPAC, DOPAC/DA ratio, NA, MHPG, MHPG/NA ratio, 5-HT, 5-HIAA, and 5-HIAA/5-HT ratio (all <italic>p</italic>-values &gt; 0.100; Figures <xref ref-type="fig" rid="F8">8C</xref>–<xref ref-type="fig" rid="F8">K</xref>).</p>
</sec>
<sec>
<title>Hypothalamus</title>
<p>Concentrations of the precursors Tyr tended to be affected by <italic>Shank1</italic> deletion in the hypothalamus (<italic>F</italic><sub>2,38</sub> = 2.902, <italic>p</italic> = 0.067; Figure <xref ref-type="fig" rid="F9">9A</xref>). Trp in the hypothalamus did not differ between genotypes (<italic>F</italic><sub>2,39</sub> = 0.864, <italic>p</italic> = 0.429; Figure <xref ref-type="fig" rid="F9">9B</xref>).</p>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>Catecholamine/indolamine, precursor, and metabolite concentrations in the hypothalamus of <italic>Shank1</italic> mice. Basal levels of <bold>(A)</bold> Tyrosine (Tyr), <bold>(B)</bold> Tryptophan (Trp), <bold>(C)</bold> Dopamine (DA), <bold>(D)</bold> DA-metabolite dehydroxyphenylacetic acid (DOPAC), <bold>(E)</bold> DOPAC/DA ratio, <bold>(F)</bold> Noradrenaline (NA), <bold>(G)</bold> NA-metabolite 4-hydroxy-3-methoxy-phenylglycol (MHPG), <bold>(H)</bold> MHPG/NA ratio, <bold>(I)</bold> 5-hydroxytryptamine (5-HT; serotonin), <bold>(J)</bold> 5-HT-metabolite 5-hydroxy-indol-acetic acid (5-HIAA), and <bold>(K)</bold> 5-HIAA/5-HT ratio in <italic>Shank1<sup>+/+</sup></italic> (black bar), <italic>Shank1<sup>+/-</sup></italic> (striped bar), and <italic>Shank1<sup>-/-</sup></italic> mice (white bar). <italic>N</italic> = 12–15 per genotype. Data are presented as means + SEM. <sup>∗</sup><italic>p</italic> &lt; 0.05. Schematic representation of the hypothalamus was adapted from <xref ref-type="bibr" rid="B68">Paxinos and Franklin (2001)</xref>.</p>
</caption>
<graphic xlink:href="fnmol-11-00419-g009"></graphic>
</fig>
<p>Moreover, the DA system was not affected by <italic>Shank1</italic> deletion. DA, DOPAC, and DOPAC/DA ratio did not differ between genotypes (all <italic>p</italic>-values &gt; 0.100; Figures <xref ref-type="fig" rid="F9">9C</xref>–<xref ref-type="fig" rid="F9">E</xref>).</p>
<p>While NA concentrations were not affected by <italic>Shank1</italic> deletion (<italic>F</italic><sub>2,37</sub> = 0.598, <italic>p</italic> = 0.555; Figure <xref ref-type="fig" rid="F9">9F</xref>), MHPG levels differed between genotypes (<italic>F</italic><sub>2,37</sub> = 3.596, <italic>p</italic> = 0.037; Figure <xref ref-type="fig" rid="F9">9G</xref>). Specifically, MHPG concentrations in the hypothalamus of <italic>Shank1<sup>-/-</sup></italic> mice were higher than <italic>Shank1<sup>+/+</sup></italic> mice (<italic>p</italic> = 0.012) but not <italic>Shank1<sup>+/-</sup></italic> mice (<italic>p</italic> = 0.263), with no difference between <italic>Shank1<sup>+/+</sup></italic> and <italic>Shank1<sup>+/-</sup></italic> mice (<italic>p</italic> = 0.121). Genotype-dependent differences in the MHPG/NA ratio were not evident (<italic>F</italic><sub>2,36</sub> = 1.041, <italic>p</italic> = 0.363; Figure <xref ref-type="fig" rid="F9">9H</xref>).</p>
<p>Finally, there were genotype-dependent differences in 5-HT concentrations in the hypothalamus (<italic>F</italic><sub>2,38</sub> = 5.437, <italic>p</italic> = 0.008; Figure <xref ref-type="fig" rid="F9">9I</xref>). While <italic>Shank1<sup>-/-</sup></italic> mice had higher 5-HT concentrations than <italic>Shank1<sup>+/+</sup></italic> mice (<italic>p</italic> = 0.002), this difference was not present between <italic>Shank1<sup>-/-</sup></italic> and <italic>Shank1<sup>+/-</sup></italic> mice (<italic>p</italic> = 0.113) or between <italic>Shank1<sup>+/+</sup></italic> and <italic>Shank1<sup>+/-</sup></italic> mice (<italic>p</italic> = 0.095). In conjunction, there was a trend for differences in 5-HIAA concentrations (<italic>F</italic><sub>2,38</sub> = 2.581, <italic>p</italic> = 0.089; Figure <xref ref-type="fig" rid="F9">9J</xref>). No genotype-dependent differences in the 5-HIAA/5-HT ratio were observed (<italic>F</italic><sub>2,38</sub> = 0.480, <italic>p</italic> = 0.622; Figure <xref ref-type="fig" rid="F9">9K</xref>).</p>
</sec>
</sec>
</sec>
<sec>
<title>Discussion</title>
<p>The goal of our present study was to test whether <italic>Shank1</italic> plays a role in the behavioral effects of psychostimulants and whether this is associated with genotype-dependent neurochemical alterations. To this aim, null mutant <italic>Shank1<sup>-/-</sup></italic> mice were treated with AMPH (2.5 mg/kg) and MDMA (20 mg/kg), and psychostimulant-induced hyperactivity was compared to heterozygous <italic>Shank1<sup>+/-</sup></italic> and wildtype <italic>Shank1<sup>+/+</sup></italic> littermate controls. Results show that <italic>Shank1<sup>-/-</sup></italic> mice display reduced psychostimulant-induced hyperactivity, although psychostimulants robustly stimulated locomotor activity in littermate controls. <italic>Shank1</italic> deletion effects emerged throughout development, were particularly prominent in adulthood, and seen in response to both psychostimulants, i.e., AMPH and MDMA.</p>
<p>Mutations in <italic>SHANK</italic> genes are associated with multiple major neuropsychiatric disorders, including SCZ and BPD besides ASD (<xref ref-type="bibr" rid="B38">Guilmatre et al., 2014</xref>; <xref ref-type="bibr" rid="B6">Bourgeron, 2015</xref>; <xref ref-type="bibr" rid="B12">de la Torre-Ubieta et al., 2016</xref>). Because psychostimulants, such as AMPH, can provoke mania-like symptoms in healthy subjects and exacerbate symptoms or induce a manic episode in BPD patients (<xref ref-type="bibr" rid="B56">Meyendorff et al., 1985</xref>; <xref ref-type="bibr" rid="B70">Peet and Peters, 1995</xref>; <xref ref-type="bibr" rid="B40">Hasler et al., 2006</xref>), we expected that <italic>Shank1</italic> deletion leads to increased AMPH-induced hyperactivity. In fact, AMPH-induced hyperactivity is a commonly applied paradigm to assess behavioral phenotypes related to BPD and considered to be the gold standard for modeling mania-like elevated drive in mouse models (<xref ref-type="bibr" rid="B4">Berggren et al., 1978</xref>; <xref ref-type="bibr" rid="B36">Gould et al., 2001</xref>; <xref ref-type="bibr" rid="B47">Kato et al., 2007</xref>; <xref ref-type="bibr" rid="B120">Young et al., 2011</xref>). Unexpectedly, however, <italic>Shank1<sup>-/-</sup></italic> mice displayed reduced psychostimulant-induced hyperactivity. This was reflected in a weaker increase in locomotor activity and a complete lack of induction of rearing behavior following AMPH. Supporting a gene dosage effect, <italic>Shank<sup>+/-</sup></italic> mice displayed an intermediate phenotype. While locomotor activity was increased following AMPH to levels similar to littermate controls, induction of rearing behavior following AMPH was absent, with rearing levels being similar to <italic>Shank1<sup>-/-</sup></italic> mice. Our observation that AMPH-induced hyperactivity is reduced rather than enhanced following <italic>Shank1</italic> deletion thus clearly speaks against a behavioral phenotype with relevance to BPD. The lack of a BPD-like phenotype is consistent with currently available human data linking mutations in <italic>SHANK2</italic> and <italic>SHANK3</italic> but not <italic>SHANK1</italic> to BPD. Specifically, a duplication in <italic>SHANK2</italic> has been reported for a BPD patient (<xref ref-type="bibr" rid="B62">Noor et al., 2014</xref>) and four point mutations in <italic>SHANK2</italic> (c.3979G &gt; A; c.2900A &gt; G; c.4461C &gt; T; c.4926G &gt; A) have been identified very recently in BPD patients (<xref ref-type="bibr" rid="B117">Yang et al., 2018</xref>). Moreover, in a substantial number of individuals lacking <italic>SHANK3</italic> and diagnosed with the Phelan-McDermid 22q13 deletion syndrome BPD was evident (<xref ref-type="bibr" rid="B92">Sovner et al., 1996</xref>; <xref ref-type="bibr" rid="B108">Willemsen et al., 2011</xref>; <xref ref-type="bibr" rid="B13">Denayer et al., 2012</xref>; <xref ref-type="bibr" rid="B101">Verhoeven et al., 2012</xref>, <xref ref-type="bibr" rid="B102">2013</xref>; <xref ref-type="bibr" rid="B103">Vucurovic et al., 2012</xref>). Notably, <italic>SHANK3</italic> duplications were also associated with BPD in humans (<xref ref-type="bibr" rid="B39">Han et al., 2013</xref>). In contrast, mutations in <italic>SHANK1</italic> have been associated with SCZ but not BPD. <xref ref-type="bibr" rid="B27">Fromer et al. (2014)</xref> reported a <italic>de novo SHANK1</italic> frameshift mutation in a SCZ patient. <xref ref-type="bibr" rid="B48">Lennertz et al. (2012)</xref> found that the T allele of the <italic>SHANK1</italic> promotor variant rs3810280 leads to impaired auditory working memory capacity as assessed with digit span in SCZ patients and subjects clinically at risk for developing a psychosis but not in healthy controls.</p>
<p>The clinical pattern is reflected in relevant <italic>Shank</italic> mouse models. For instance, <xref ref-type="bibr" rid="B67">Pappas et al. (2017)</xref> recently reported BPD-like phenotypes in <italic>Shank2<sup>Δ24-/-</sup></italic> mice. Specifically, they observed increased locomotor activity indicative of elevated drive and perturbed circadian rhythms, which could be normalized by lithium and valproate treatment. Importantly, the increase in locomotor activity caused by <italic>Shank2</italic> deletion could be augmented by AMPH administration and the augmentation was more prominent in <italic>Shank2<sup>Δ24-/-</sup></italic> mice than in <italic>Shank2<sup>Δ24+/+</sup></italic> controls (<xref ref-type="bibr" rid="B67">Pappas et al., 2017</xref>). <italic>Shank2</italic> deficiency limited to the forebrain recapitulated the BPD-like phenotype, which was associated with alterations in the composition and function of NMDA and AMPA receptors (<xref ref-type="bibr" rid="B67">Pappas et al., 2017</xref>). Moreover, <italic>Shank2<sup>Δ7-/-</sup></italic> mice likewise display enhanced levels of locomotor activity but augmentation by methylphenidate was weaker in <italic>Shank2<sup>Δ7-/-</sup></italic> mice than in <italic>Shank2<sup>Δ7+/+</sup></italic> controls (<xref ref-type="bibr" rid="B22">Ey et al., 2018</xref>). Finally, <italic>Shank3</italic> overexpression in mice was linked to a BPD-like phenotype characterized by increased locomotor activity and abnormal circadian rhythms (<xref ref-type="bibr" rid="B39">Han et al., 2013</xref>). Importantly, hyperactivity of <italic>Shank3</italic> overexpressing mice following an acute injection of AMPH aggravated to a greater extent than in controls. The BPD-like phenotype was rescued by valproate but not lithium treatment. To our knowledge, no studies on <italic>Shank3</italic> deletion effects on AMPH-induced hyperactivity are available. Together, this might suggest that <italic>Shank1</italic> deletion leads to specific alterations in brain structure or function reducing rather than enhancing the efficacy of AMPH to stimulate hyperactivity not present in other relevant <italic>Shank</italic> mouse models.</p>
<p>Sold as speed, AMPH is among the most commonly used illicit drugs, but is also available by prescription and is widely used for treating weight control, narcolepsy, and attention deficit disorder (<xref ref-type="bibr" rid="B94">Sulzer et al., 2005</xref>). AMPH acts primarily as a DA and NA releaser by induction of reverse transport of catecholamines through plasma membrane uptake carries, i.e., the DA and NA transporters, and redistribution of catecholamines from synaptic vesicles to the cytosol, with little affinity for receptors (<xref ref-type="bibr" rid="B94">Sulzer et al., 2005</xref>; <xref ref-type="bibr" rid="B44">Hutson et al., 2014</xref>), although prominent effects on the 5-HT system were also reported (<xref ref-type="bibr" rid="B77">Pum et al., 2007</xref>). In mice, the stimulatory effects of AMPH are widely believed to be driven by increased synaptic DA levels and subsequent activation of postsynaptic receptors. In fact, while mice deficient for the NA transporter are supersensitive (<xref ref-type="bibr" rid="B114">Xu F. et al., 2000</xref>), AMPH-induced hyperactivity is enhanced in DA transporter overexpressing mice (<xref ref-type="bibr" rid="B82">Salahpour et al., 2008</xref>) but completely abolished in mice lacking the DA transporter (<xref ref-type="bibr" rid="B35">Giros et al., 1996</xref>), an effect mediated by the 5-HT system (<xref ref-type="bibr" rid="B28">Gainetdinov et al., 1999</xref>). Yet, it is not affected by deletion of the gene for the 5-HT transporter (<xref ref-type="bibr" rid="B2">Bengel et al., 1998</xref>), although, to a lesser extent, AMPH affects 5-HT transporters as well (<xref ref-type="bibr" rid="B93">Steele et al., 1987</xref>; <xref ref-type="bibr" rid="B11">Crespi et al., 1997</xref>). Postsynaptically, AMPH action was reported to depend on D2 but less on D3 and not on D4 receptors, with mixed results for the D1 receptor (<xref ref-type="bibr" rid="B115">Xu M. et al., 2000</xref>; <xref ref-type="bibr" rid="B55">McNamara et al., 2006</xref>; <xref ref-type="bibr" rid="B23">Fan and Hess, 2007</xref>; <xref ref-type="bibr" rid="B24">Fan et al., 2010</xref>). Various 5-HT receptors play a modulating role as well and it was shown that AMPH-induced hyperactivity is increased in 5-HT1A (<xref ref-type="bibr" rid="B100">van den Buuse et al., 2011</xref>), 5-HT1B (<xref ref-type="bibr" rid="B7">Bronsert et al., 2001</xref>), and 5-HT2A (<xref ref-type="bibr" rid="B83">Salomon et al., 2007</xref>) receptor knockout mice. Partially conflicting evidence was obtained in pharmacological studies, with 8-OH-DPAT (<xref ref-type="bibr" rid="B75">Przegalinski et al., 2000</xref>) and SB216641 (<xref ref-type="bibr" rid="B76">Przegalinski et al., 2001</xref>), 5-HT1A agonist and 5-HT1B antagonist, respectively, reducing AMPH-induced hyperactivity, while CP94,253, a 5-HT1B agonist, further enhances AMPH-induced hyperactivity (<xref ref-type="bibr" rid="B76">Przegalinski et al., 2001</xref>). Mixed results were obtained for the 5-HT2A (<xref ref-type="bibr" rid="B9">Carlsson et al., 1999</xref>; <xref ref-type="bibr" rid="B91">Sorensen et al., 1993</xref>) and the 5-HT2C (<xref ref-type="bibr" rid="B64">O’Neill et al., 1999</xref>; <xref ref-type="bibr" rid="B54">Marquis et al., 2007</xref>) receptor. For a more comprehensive overview including other species besides mice, the reader is referred to two excellent reviews (<xref ref-type="bibr" rid="B44">Hutson et al., 2014</xref>; <xref ref-type="bibr" rid="B60">Müller and Homberg, 2015</xref>).</p>
<p>While AMPH-induced hyperactivity was reduced but still detectable in <italic>Shank1<sup>-/-</sup></italic> mice, MDMA-induced hyperactivity was robustly blocked and completely absent in <italic>Shank1<sup>-/-</sup></italic> mice. Because a genetic manipulation affecting psychostimulant-induced hyperactivity may easily look like an attenuation when the dose-response curve is in fact shifted to the left, but now producing motor stereotypies instead of ambulation, we measured repetitive circling behavior (<xref ref-type="bibr" rid="B74">Powell et al., 2004</xref>; <xref ref-type="bibr" rid="B78">Risbrough et al., 2006</xref>). We focused on mice treated with MDMA, mostly for two reasons. Firstly, the <italic>Shank1</italic> deletion effect was most prominent in response to MDMA. Secondly, the MDMA dose applied here can be considered relatively high, making it particularly likely that motor stereotypies, such as repetitive circling behavior occur. However, while there was an overall increase in repetitive circling behavior following MDMA treatment, the increase in circling occurred irrespective of genotype and can thus not explain the lack of MDMA-induced hyperactivity in <italic>Shank1<sup>-/-</sup></italic> mice. Although this speaks against a dose-response curve that is shifted to the left following <italic>Shank1</italic> deletion, a future dose-response study including several MDMA doses appears warranted.</p>
<p>Sold as ecstasy, MDMA is also among the most widely used illicit drugs, yet with little therapeutic use (<xref ref-type="bibr" rid="B94">Sulzer et al., 2005</xref>). MDMA acts primarily as a 5-HT and DA releaser by blocking reuptake transporters. However, relative to AMPH, MDMA is more potent at releasing 5-HT than DA (<xref ref-type="bibr" rid="B93">Steele et al., 1987</xref>; <xref ref-type="bibr" rid="B11">Crespi et al., 1997</xref>). In mice, it was repeatedly shown that MDMA leads to hyperactivity, and hyperactivity induced by low doses of MDMA of up to 10 mg/kg has previously been found to be blocked by deletion of the genes for either the 5-HT1B receptor (<xref ref-type="bibr" rid="B86">Scearce-Levie et al., 1999</xref>; <xref ref-type="bibr" rid="B45">Jean et al., 2012</xref>), the 5-HT2B receptor (<xref ref-type="bibr" rid="B17">Doly et al., 2008</xref>; <xref ref-type="bibr" rid="B16">Doly et al., 2009</xref>), or the 5-HT transporter (<xref ref-type="bibr" rid="B2">Bengel et al., 1998</xref>), while it is potentiated in 5-HT2A receptor knockout mice (<xref ref-type="bibr" rid="B65">Orejarena et al., 2011</xref>). Consistently, MDMA-induced hyperactivity was reported to be reduced by the 5-HT1B antagonist GR127935 (<xref ref-type="bibr" rid="B86">Scearce-Levie et al., 1999</xref>), the 5-HT2B antagonist RS127445 (<xref ref-type="bibr" rid="B17">Doly et al., 2008</xref>; <xref ref-type="bibr" rid="B16">Doly et al., 2009</xref>), the 5-HT2C antagonist RS102221 (<xref ref-type="bibr" rid="B10">Conductier et al., 2005</xref>), the 5-HT4 antagonist RS39604 (<xref ref-type="bibr" rid="B45">Jean et al., 2012</xref>), and the 5-HT uptake inhibitor fluoxetine (<xref ref-type="bibr" rid="B25">Fantegrossi et al., 2003</xref>). Higher MDMA doses, however, induced late-phase increases in hyperactivity in 5-HT1B (<xref ref-type="bibr" rid="B86">Scearce-Levie et al., 1999</xref>) and 5-HT2B (<xref ref-type="bibr" rid="B16">Doly et al., 2009</xref>) receptor knockout mice, possibly due to a delayed increase in DA release (<xref ref-type="bibr" rid="B106">White et al., 1994</xref>, <xref ref-type="bibr" rid="B107">1996</xref>; <xref ref-type="bibr" rid="B116">Yamamoto and Spanos, 1988</xref>). <xref ref-type="bibr" rid="B78">Risbrough et al. (2006)</xref> found that late-phase increases in hyperactivity evoked by MDMA are enhanced in D1 knockout mice but reduced in D2 and D3 knockout mice. In DA transporter knockout mice, the typical hyperactivity displayed by these mice is reduced in response to MDMA (<xref ref-type="bibr" rid="B74">Powell et al., 2004</xref>). <xref ref-type="bibr" rid="B3">Benturquia et al. (2008)</xref> reported that MDMA-induced hyperactivity is antagonized by SCH23390, a D1 antagonist. Alike for AMPH, the reader is referred to two excellent reviews for a more comprehensive overview including other species besides mice (<xref ref-type="bibr" rid="B94">Sulzer et al., 2005</xref>; <xref ref-type="bibr" rid="B60">Müller and Homberg, 2015</xref>).</p>
<p>Very little is known about interactions between SHANK1 and the major neurotransmitters affected by AMPH and MDMA, i.e., DA, NA, and 5-HT. <xref ref-type="bibr" rid="B1">Azdad et al. (2009)</xref> obtained evidence indicating that in striatal neurons D2 receptors regulate NMDA-mediated neuronal excitation resulting in a depolarized plateau potential and spike firing through a mechanism requiring scaffolding proteins of the SHANK family including SHANK1. <xref ref-type="bibr" rid="B8">Buonaguro et al. (2017)</xref> showed that 3 weeks of treatment with the D2 antagonist haloperidol led to a reduction of SHANK1 mRNA expression in the anterior cingulate cortex and the insula as well as the nucleus accumbens. <xref ref-type="bibr" rid="B49">Li et al. (2015)</xref> reported that vortioxetine but not fluoxetine treatment leads to enhanced levels of SHANK1 mRNA in the hippocampus. Vortioxetine acts through increasing 5-HT concentrations in the synaptic cleft by inhibiting reuptake and through modulating 5-HT receptors. Finally, <xref ref-type="bibr" rid="B66">Pal and Das (2013)</xref> reported upregulation of SHANK1 mRNA and protein levels in cortex and midbrain following chronic morphine treatment.</p>
<p>In an initial effort to better understand the effects of <italic>Shank1</italic> deletion on the neurochemical architecture, we analyzed DA, NA, and 5-HT neurotransmitter concentrations together with their precursors and metabolites in relevant brain structures, namely prefrontal cortex, nucleus accumbens, and hypothalamus. In the prefrontal cortex, which plays a key role in maintaining inhibitory control over striatal mechanisms involved in the effects of drugs of abuse (<xref ref-type="bibr" rid="B21">Everitt and Robbins, 2016</xref>), basal DA levels tended to be affected by <italic>Shank1</italic> deletion, with lower DA concentrations in <italic>Shank1<sup>-/-</sup></italic> mice. Moreover, the concentration of the DA metabolite DOPAC differed between genotypes and DOPAC levels were reduced in <italic>Shank1<sup>-/-</sup></italic> mice. The DOPAC/DA ratio, however, was not affected. Concentrations of the DA precursor Tyr also did not differ between genotypes. Besides DA, basal NA concentrations in the prefrontal cortex were affected by <italic>Shank1</italic> deletion, with higher NA concentrations in <italic>Shank1<sup>-/-</sup></italic> mice. There were no differences between genotypes in the concentrations of the NA metabolite MHPG, yet the MHPG/NA ratio differed between genotypes and was lower in <italic>Shank1<sup>-/-</sup></italic> mice. Importantly, the decreased MHPG/NA ratio in <italic>Shank1<sup>-/-</sup></italic> mice, which was paralleled by increases in NA concentrations in absence of changes in MHPG, might indicate decreased NA metabolism in <italic>Shank1<sup>-/-</sup></italic> mice. Finally, <italic>Shank1</italic> deletion affected the level of the 5-HT precursor Trp in the prefrontal cortex, with <italic>Shank1<sup>-/-</sup></italic> mice having higher Trp concentrations. However, basal 5-HT concentrations, the levels of the main 5-HT metabolite 5-HIAA, and the 5-HIAA/5-HT ratio did not differ between genotypes.</p>
<p>In the nucleus accumbens, a key brain structure strongly implicated in the rewarding actions of drugs of abuse (<xref ref-type="bibr" rid="B21">Everitt and Robbins, 2016</xref>), <italic>Shank1</italic> deletion affected the concentration of the DA precursor Tyr and the 5-HT precursor Trp, with the levels of both precursors being higher in <italic>Shank1<sup>-/-</sup></italic> mice. Despite these genotype differences in the levels of the precursors, DA, NA, and 5-HT concentrations as well as their metabolites were not affected in this brain region.</p>
<p>In the hypothalamus, a brain region less heavily involved in the actions of drugs of abuse (<xref ref-type="bibr" rid="B21">Everitt and Robbins, 2016</xref>), no prominent genotype effects on the levels of the precursors Tyr and Trp were evident and DA, DOPAC as well as the DOPAC/DA ratio also did not differ between genotypes. However, while NA concentrations were not affected by <italic>Shank1</italic> deletion, MHPG levels were higher in the hypothalamus of <italic>Shank1<sup>-/-</sup></italic> mice. Genotype-dependent differences in the MHPG/NA ratio were not evident. Finally, there were genotype-dependent differences in 5-HT concentrations in the hypothalamus, with <italic>Shank1<sup>-/-</sup></italic> mice having higher concentrations. In conjunction, there was a trend for a similar genotype pattern in 5-HIAA concentrations. No genotype-dependent differences in the 5-HIAA/5-HT ratio were observed.</p>
<p>Together, this shows that <italic>Shank1</italic> deletion leads to alterations in the neurochemical architecture of the brain regions evaluated, with most prominent effects being evident in the prefrontal cortex. This is remarkable because SHANK1 expression is particularly high in cortex, but low in striatum and hypothalamus (<xref ref-type="bibr" rid="B69">Peça et al., 2011</xref>), suggesting local effects of <italic>Shank1</italic> deletion. It is tempting to speculate that the opposite alterations in DA and NA concentrations together with the decreased NA metabolism in the prefrontal cortex of <italic>Shank1<sup>-/-</sup></italic> mice affect the fronto-striatal circuitry in mediating inhibitory control. Reduced prefrontal inhibitory control was strongly implicated in dominance of subcortically mediated responding to drugs of abuse (<xref ref-type="bibr" rid="B21">Everitt and Robbins, 2016</xref>). Of note, the increase of Trp in prefrontal cortex and nucleus accumbens is interesting because the essential amino acid Trp is not only the precursor of 5-HT, but also gives rise to melatonin and kynurenines, which have all been implicated, in one or the other way, in ASD, SCZ, and BPD (<xref ref-type="bibr" rid="B58">Morera-Fumero and Abreu-Gonzalez, 2013</xref>; <xref ref-type="bibr" rid="B80">Rossignol and Frye, 2014</xref>; <xref ref-type="bibr" rid="B33">Geoffroy et al., 2015</xref>; <xref ref-type="bibr" rid="B50">Lim et al., 2016</xref>; <xref ref-type="bibr" rid="B20">Erhardt et al., 2017</xref>).</p>
<p>To our knowledge, it is currently not known whether <italic>Shank1</italic> deletion affects the expression and/or function of the AMPH and MDMA targets, i.e., plasma membrane uptake carries for DA, NA, and 5-HT. Because reduced efficacy to stimulate hyperactivity in <italic>Shank1<sup>-/-</sup></italic> mice is seen in response to both AMPH and MDMA, alterations in the NA transporter are not prime candidates driving the effects. Another candidate for the reduced efficacy of psychostimulants to stimulate hyperactivity in <italic>Shank1<sup>-/-</sup></italic> mice is the DA transporter. Although reduced expression and/or function of the DA transporter could explain reduced efficacy of psychostimulants, this also appears unlikely to be the case. This is because DA transporter knockout mice display increased locomotor activity under drug free conditions (<xref ref-type="bibr" rid="B35">Giros et al., 1996</xref>; <xref ref-type="bibr" rid="B28">Gainetdinov et al., 1999</xref>; <xref ref-type="bibr" rid="B74">Powell et al., 2004</xref>), whereas <italic>Shank1</italic> deletion leads to mild hypoactivity (<xref ref-type="bibr" rid="B43">Hung et al., 2008</xref>; <xref ref-type="bibr" rid="B89">Silverman et al., 2011</xref>; <xref ref-type="bibr" rid="B112">Wöhr et al., 2011</xref>). Finally, the 5-HT transporter appears of relevance because MDMA-induced hyperactivity is abolished in mice lacking the 5-HT transporter (<xref ref-type="bibr" rid="B2">Bengel et al., 1998</xref>), yet this as well does not explain the full result pattern because AMPH-induced hyperactivity is not affected by deletion of the gene for the 5-HT transporter (<xref ref-type="bibr" rid="B2">Bengel et al., 1998</xref>). Of note, the time spent in the center was not affected by AMPH or MDMA treatment in a genotype-dependent manner and the reduction in center time seen following <italic>Shank1</italic> deletion might reflect a mild increase in anxiety levels and is consistent with the literature (<xref ref-type="bibr" rid="B43">Hung et al., 2008</xref>; <xref ref-type="bibr" rid="B89">Silverman et al., 2011</xref>). Together, this might thus indicate that postsynaptic receptors implicated in psychostimulant-induced hyperactivity, such as D1 and D2 (<xref ref-type="bibr" rid="B115">Xu M. et al., 2000</xref>; <xref ref-type="bibr" rid="B23">Fan and Hess, 2007</xref>; <xref ref-type="bibr" rid="B24">Fan et al., 2010</xref>) as well as 5-HT1B (<xref ref-type="bibr" rid="B86">Scearce-Levie et al., 1999</xref>; <xref ref-type="bibr" rid="B45">Jean et al., 2012</xref>) and 5-HT2B (<xref ref-type="bibr" rid="B17">Doly et al., 2008</xref>; <xref ref-type="bibr" rid="B16">Doly et al., 2009</xref>) receptors, drive the effects of <italic>Shank1</italic> deletion. However, to our knowledge, there is no study on the expression of relevant receptors in mice lacking SHANK1 available. Future studies on the effects of <italic>Shank1</italic> deletion on DA, NA, and 5-HT transporters and receptors appear therefore warranted.</p>
<p>As master scaffolding proteins enriched in the PSD at excitatory glutamatergic synapses, SHANKs anchor glutamate receptors and link them to the actin cytoskeleton and postsynaptic signaling pathways (<xref ref-type="bibr" rid="B99">Ting et al., 2012</xref>; <xref ref-type="bibr" rid="B81">Sala et al., 2015</xref>). In the first study on the effects of <italic>Shank1</italic> deletion, <xref ref-type="bibr" rid="B43">Hung et al. (2008)</xref> focused on the forebrain and hippocampus and demonstrated that <italic>Shank1</italic> is important for regulating dendritic spine morphology and synaptic strength. Standard measures of synaptic plasticity, however, were unchanged, with intact hippocampal long-term potentiation. NMDA, AMPA, and metabotropic glutamate receptors were also not affected (<xref ref-type="bibr" rid="B43">Hung et al., 2008</xref>). AMPA and NMDA receptors appear to play a role in acquisition and reinstatement of conditioned place preference, as, for instance, induced by MDMA (<xref ref-type="bibr" rid="B29">García-Pardo et al., 2015</xref>; <xref ref-type="bibr" rid="B30">García-Pardo et al., 2018</xref>).</p>
<p>More recently, <xref ref-type="bibr" rid="B95">Sungur et al. (2017)</xref> studied the effects of <italic>Shank1</italic> deletion on protein expression levels of the brain-derived neurotrophic factor BDNF together with its epigenetic regulation. Partial genetic depletion of BDNF was repeatedly associated with stronger AMPH-induced hyperactivity and associated with increased striatal DA concentrations (<xref ref-type="bibr" rid="B15">Dluzen et al., 2001</xref>; <xref ref-type="bibr" rid="B85">Saylor and McGinty, 2008</xref>; <xref ref-type="bibr" rid="B51">Manning et al., 2016</xref>). Similar findings were obtained for MDMA (<xref ref-type="bibr" rid="B59">Mouri et al., 2017</xref>). <xref ref-type="bibr" rid="B95">Sungur et al. (2017)</xref> found that <italic>Shank1</italic> deletion has no effect on basal BDNF expression levels, yet in response to learning a memory task hippocampal BDNF expression was particularly enhanced in <italic>Shank1<sup>-/-</sup></italic> mice. A subsequent investigation of the epigenetic regulation revealed enrichment of histone H3 acetylation at the <italic>Bdnf</italic> promoter1 in <italic>Shank1<sup>-/-</sup></italic> mice. Because BDNF is an important regulator of gene expression stimulating D3 receptor expression (<xref ref-type="bibr" rid="B37">Guillin et al., 2001</xref>) and D3 receptor activation was reported to inhibit psychostimulant-induced hyperactivity (<xref ref-type="bibr" rid="B55">McNamara et al., 2006</xref>), altered BDNF expression and its epigenetic regulation might thus be associated with the reduced efficacy of psychostimulants to stimulate hyperactivity in <italic>Shank1<sup>-/-</sup></italic> mice.</p>
<p>Finally, another relevant factor that possibly contributes to the reduced efficacy of psychostimulants in <italic>Shank1<sup>-/-</sup></italic> mice might be parvalbumin (PV) expression. PV is a calcium-binding protein important for the maintenance of the excitation/inhibition balance in the brain (<xref ref-type="bibr" rid="B42">Hu et al., 2014</xref>), repeatedly associated with major neuropsychiatric disorders, including ASD, SCZ, and BPD (<xref ref-type="bibr" rid="B53">Marín, 2012</xref>). Acute AMPH treatment stimulates robust firing of striatal PV-positive GABAergic interneurons (<xref ref-type="bibr" rid="B109">Wiltschko et al., 2010</xref>). Moreover, AMPH was reported to induce expression of the activity-inducible transcription factor Fos in PV-positive GABAergic interneurons in the nucleus accumbens, together with phosphorylation of the methyl-DNA-binding protein MeCP2 at Ser421 (<xref ref-type="bibr" rid="B14">Deng et al., 2010</xref>), the latter being associated with SHANK1 protein expression (<xref ref-type="bibr" rid="B18">Du et al., 2016</xref>). Very recently, it was further shown that AMPH treatment in mice with silenced PV-positive GABAergic interneurons evoked stronger activation in both D1 and D2 receptor-expressing medium spiny neurons in the nucleus accumbens (<xref ref-type="bibr" rid="B104">Wang et al., 2018</xref>). Importantly, silencing PV-positive GABAergic interneurons in the nucleus accumbens selectively inhibited the expression of locomotor sensitization following repeated injections of AMPH and blocked AMPH-induced conditioned place preference without affecting AMPH-induced DA release and hyperactivity (<xref ref-type="bibr" rid="B104">Wang et al., 2018</xref>). This is relevant because SHANK1 protein is highly co-localized with PV-expressing fast-spiking inhibitory interneurons (<xref ref-type="bibr" rid="B52">Mao et al., 2015</xref>) and <italic>Shank1</italic> deletion was shown to result in reduced PV expression (<xref ref-type="bibr" rid="B26">Filice et al., 2016</xref>). It would thus be interesting to test whether psychostimulant-induced hyperactivity is altered in PV-deficient mice, which display behavioral phenotypes with relevance to ASD (<xref ref-type="bibr" rid="B111">Wöhr et al., 2015</xref>). Specifically, <xref ref-type="bibr" rid="B26">Filice et al. (2016)</xref> found that the reduction of PV-immunoreactive neurons caused by <italic>Shank1</italic> deletion was due to a reduction in <italic>Pvalb</italic> mRNA and PV protein, without any indication for PV-expressing GABAergic interneuron loss. Importantly, PV protein expression levels were selectively decreased in those brain regions normally expressing high levels of SHANK1, such as the somatosensory cortex. However, no evidence for effects of <italic>Shank1</italic> deletion was obtained in the striatum, a region with low SHANK1 expression levels in <italic>Shank1<sup>+/+</sup></italic> mice, similar to the local effects on neurochemical architecture in the present study.</p>
</sec>
<sec>
<title>Conclusion</title>
<p><italic>Shank1<sup>-/-</sup></italic> mice display reduced psychostimulant-induced hyperactivity, although psychostimulants robustly stimulated locomotor activity in littermate controls. <italic>Shank1</italic> deletion effects emerged throughout development, were particularly prominent in adulthood, and seen in response to both psychostimulants, i.e., AMPH and MDMA. Specifically, while AMPH-induced hyperactivity was reduced but still detectable in <italic>Shank1<sup>-/-</sup></italic> mice, MDMA-induced hyperactivity was robustly blocked and completely absent in <italic>Shank1<sup>-/-</sup></italic> mice. Reduced efficacy of psychostimulants to stimulate hyperactivity in <italic>Shank1<sup>-/-</sup></italic> mice might be associated with alterations in the neurochemical architecture in prefrontal cortex, nucleus accumbens, and hypothalamus. Our observation that psychostimulant-induced hyperactivity is reduced rather than enhanced in <italic>Shank1<sup>-/-</sup></italic> mice clearly speaks against a behavioral phenotype with relevance to BPD. Lack of BPD-like phenotype is consistent with currently available human data linking mutations in <italic>SHANK2</italic> and <italic>SHANK3</italic> but not <italic>SHANK1</italic> to BPD.</p>
</sec>
<sec>
<title>Author Contributions</title>
<p>AS, TR, EA, and WD performed the experiments and/or data analysis. AS, RS, AdR, and MW wrote the manuscript. AS, AdR, and MW designed the study and supervised the project. MW acquired funding. All authors were involved in data interpretation.</p>
</sec>
<sec>
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> This work was supported by a grant from the Deutsche Forschungsgemeinschaft to MW (DFG; WO 1732/1-1).</p>
</fn>
</fn-group>
<ack>
<p>The authors wish to thank Jacqueline Crawley, University of California Davis School of Medicine, and the Howard Hughes Medical Institute investigators Albert Hung and Morgan Sheng for providing the <italic>Shank1</italic> mouse line. The authors also wish to thank Dr. J. Wildmann, Philipps-University of Marburg, for his help in this project.</p>
</ack>
<sec sec-type="supplementary material">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fnmol.2018.00419/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fnmol.2018.00419/full#supplementary-material</ext-link></p>
<supplementary-material content-type="local-data" id="SM1">
<label>FIGURE S1</label>
<caption>
<p>Time spent in the center in juvenile <italic>Shank1</italic> mice treated with AMPH. <bold>(A–C)</bold> Bar graphs depicting the time spent in the center by <italic>Shank1<sup>+/+</sup></italic> (black bar), <italic>Shank1<sup>+/-</sup></italic> (striped bar), and <italic>Shank1<sup>-/-</sup></italic> (white bar). Center time was compared during baseline testing <bold>(A)</bold>, following saline administration <bold>(B)</bold>, and after AMPH treatment <bold>(C)</bold>. Data are presented as means + SEM. <sup>∗</sup><italic>p</italic> &lt; 0.05, <sup>∗∗</sup><italic>p</italic> &lt; 0.001.</p>
</caption>
<media xlink:href="Image_1.JPEG">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="SM2">
<label>FIGURE S2</label>
<caption>
<p>AMPH-induced rearing behavior in adult <italic>Shank1</italic> mice. <bold>(A–C)</bold> Bar graphs and <bold>(A′–C′)</bold> line graphs depicting the rearing behavior by <italic>Shank1<sup>+/+</sup></italic> (black bar/black circle), <italic>Shank1<sup>+/-</sup></italic> (striped bar/white circle), and <italic>Shank1<sup>-/-</sup></italic> (white bar/black triangle). Rearing behavior was compared during baseline testing <bold>(A,A′)</bold>, following saline administration <bold>(B,B′)</bold>, and after AMPH treatment <bold>(C,C′)</bold>. Data are presented as means + SEM or means ± SEM. <sup>∗∗</sup><italic>p</italic> &lt; 0.001.</p>
</caption>
<media xlink:href="Image_2.JPEG">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="SM3">
<label>FIGURE S3</label>
<caption>
<p>Time spent in the center in adult <italic>Shank1</italic> mice treated with AMPH. <bold>(A–C)</bold> Bar graphs depicting the time spent in the center by <italic>Shank1<sup>+/+</sup></italic> (black bar), <italic>Shank1<sup>+/-</sup></italic> (striped bar), and <italic>Shank1<sup>-/-</sup></italic> (white bar). Center time was compared during baseline testing <bold>(A)</bold>, following saline administration <bold>(B)</bold>, and after AMPH treatment <bold>(C)</bold>. Data are presented as means + SEM. <sup>∗</sup><italic>p</italic> &lt; 0.05.</p>
</caption>
<media xlink:href="Image_3.JPEG">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="SM4">
<label>FIGURE S4</label>
<caption>
<p>Time spent in the center in adult <italic>Shank1</italic> mice treated with MDMA. <bold>(A–C)</bold> Bar graphs depicting the time spent in the center by <italic>Shank1<sup>+/+</sup></italic> (black bar), <italic>Shank1<sup>+/-</sup></italic> (striped bar), and <italic>Shank1<sup>-/-</sup></italic> (white bar). Center time was compared during baseline testing <bold>(A)</bold>, following saline administration <bold>(B)</bold>, and after MDMA treatment <bold>(C)</bold>. Data are presented as means + SEM. <sup>∗</sup><italic>p</italic> &lt; 0.05.</p>
</caption>
<media xlink:href="Image_4.JPEG">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="SM5">
<label>FIGURE S5</label>
<caption>
<p>MDMA-induced repetitive and stereotyped circling behavior in adult <italic>Shank1</italic> mice treated with MDMA. <bold>(A)</bold> Bar graph depicting the circling behavior displayed by all genotypes following saline administration (blue bar) and after MDMA treatment (orange bar). <bold>(A′)</bold> Line graph depicting the circling behavior displayed by <italic>Shank1<sup>+/+</sup></italic> (black circle), <italic>Shank1<sup>+/-</sup></italic> (white circle), and <italic>Shank1<sup>-/-</sup></italic> (black triangle) over two consecutive test days, i.e., following saline administration (blue are) and after MDMA treatment (orange area). Data are presented as means + SEM or means ± SEM. <sup>##</sup><italic>p</italic> &lt; 0.001 <bold>(A)</bold>, <sup>#</sup><italic>p</italic> &lt; 0.05 and <sup>##</sup><italic>p</italic> &lt; 0.001 vs. day 2 <bold>(A′)</bold>.</p>
</caption>
<media xlink:href="Image_5.JPEG">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azdad</surname><given-names>K.</given-names></name><name><surname>Gall</surname><given-names>D.</given-names></name><name><surname>Woods</surname><given-names>A. S.</given-names></name><name><surname>Ledent</surname><given-names>C.</given-names></name><name><surname>Ferré</surname><given-names>S.</given-names></name><name><surname>Schiffmann</surname><given-names>S. N.</given-names></name></person-group> (<year>2009</year>). <article-title>Dopamine D2 and adenosine A2A receptors regulate NMDA-mediated excitation in accumbens neurons through A2A-D2 receptor heteromerization.</article-title>
<source/><italic>Neuropsychopharmacology</italic>
<volume>34</volume>
<fpage>972</fpage>–<lpage>986</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2008.144</pub-id>
<pub-id pub-id-type="pmid">18800071</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bengel</surname><given-names>D.</given-names></name><name><surname>Murphy</surname><given-names>D. L.</given-names></name><name><surname>Andrews</surname><given-names>A. M.</given-names></name><name><surname>Wichems</surname><given-names>C. H.</given-names></name><name><surname>Feltner</surname><given-names>D.</given-names></name><name><surname>Heils</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>1998</year>). <article-title>Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine (“Ecstasy”) in serotonin transporter-deficient mice.</article-title>
<source/><italic>Mol. Pharmacol.</italic>
<volume>53</volume>
<fpage>649</fpage>–<lpage>655</lpage>. <pub-id pub-id-type="doi">10.1124/mol.53.4.649</pub-id>
<pub-id pub-id-type="pmid">9547354</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benturquia</surname><given-names>N.</given-names></name><name><surname>Courtin</surname><given-names>C.</given-names></name><name><surname>Noble</surname><given-names>F.</given-names></name><name><surname>Marie-Claire</surname><given-names>C.</given-names></name></person-group> (<year>2008</year>). <article-title>Involvement of D1 dopamine receptor in MDMA-induced locomotor activity and striatal gene expression in mice.</article-title>
<source/><italic>Brain Res.</italic>
<volume>1211</volume>
<fpage>1</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2008.03.016</pub-id>
<pub-id pub-id-type="pmid">18433738</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berggren</surname><given-names>U.</given-names></name><name><surname>Tallstedt</surname><given-names>L.</given-names></name><name><surname>Ahlenius</surname><given-names>S.</given-names></name><name><surname>Engel</surname><given-names>J.</given-names></name></person-group> (<year>1978</year>). <article-title>The effect of lithium on amphetamine-induced locomotor stimulation.</article-title>
<source/><italic>Psychopharmacology</italic>
<volume>59</volume>
<fpage>41</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1007/BF00428028</pub-id><pub-id pub-id-type="pmid">100811</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berkel</surname><given-names>S.</given-names></name><name><surname>Marshall</surname><given-names>C. R.</given-names></name><name><surname>Weiss</surname><given-names>B.</given-names></name><name><surname>Howe</surname><given-names>J.</given-names></name><name><surname>Roeth</surname><given-names>R.</given-names></name><name><surname>Moog</surname><given-names>U.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation.</article-title>
<source/><italic>Nat. Genet.</italic>
<volume>42</volume>
<fpage>489</fpage>–<lpage>491</lpage>. <pub-id pub-id-type="doi">10.1038/ng.589</pub-id>
<pub-id pub-id-type="pmid">20473310</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourgeron</surname><given-names>T.</given-names></name></person-group> (<year>2015</year>). <article-title>From the genetic architecture to synaptic plasticity in autism spectrum disorder.</article-title>
<source/><italic>Nat. Rev. Neurosci.</italic>
<volume>16</volume>
<fpage>551</fpage>–<lpage>563</lpage>. <pub-id pub-id-type="doi">10.1038/nrn3992</pub-id>
<pub-id pub-id-type="pmid">26289574</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bronsert</surname><given-names>M. R.</given-names></name><name><surname>Mead</surname><given-names>A. N.</given-names></name><name><surname>Hen</surname><given-names>R.</given-names></name><name><surname>Rocha</surname><given-names>B. A.</given-names></name></person-group> (<year>2001</year>). <article-title>Amphetamine-induced locomotor activation in 5-HT(1B) knockout mice: effects of injection route on acute and sensitized responses.</article-title>
<source/><italic>Behav. Pharmacol.</italic>
<volume>12</volume>
<fpage>549</fpage>–<lpage>555</lpage>. <pub-id pub-id-type="doi">10.1097/00008877-200111000-00017</pub-id>
<pub-id pub-id-type="pmid">11795245</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buonaguro</surname><given-names>E. F.</given-names></name><name><surname>Iasevoli</surname><given-names>F.</given-names></name><name><surname>Marmo</surname><given-names>F.</given-names></name><name><surname>Eramo</surname><given-names>A.</given-names></name><name><surname>Latte</surname><given-names>G.</given-names></name><name><surname>Avagliano</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Re-arrangements of gene transcripts at glutamatergic synapses after prolonged treatments with antipsychotics: a putative link with synaptic remodeling.</article-title>
<source/><italic>Prog. Neuropsychopharmacol. Biol. Psychiatry</italic>
<volume>76</volume>
<fpage>29</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2017.02.012</pub-id>
<pub-id pub-id-type="pmid">28235555</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlsson</surname><given-names>M. L.</given-names></name><name><surname>Martin</surname><given-names>P.</given-names></name><name><surname>Nilsson</surname><given-names>M.</given-names></name><name><surname>Sorensen</surname><given-names>S. M.</given-names></name><name><surname>Carlsson</surname><given-names>A.</given-names></name><name><surname>Waters</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>1999</year>). <article-title>The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice.</article-title>
<source/><italic>J. Neural Transm.</italic>
<volume>106</volume>
<fpage>123</fpage>–<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1007/s007020050144</pub-id>
<pub-id pub-id-type="pmid">10226932</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conductier</surname><given-names>G.</given-names></name><name><surname>Crosson</surname><given-names>C.</given-names></name><name><surname>Hen</surname><given-names>R.</given-names></name><name><surname>Bockaert</surname><given-names>J.</given-names></name><name><surname>Compan</surname><given-names>V.</given-names></name></person-group> (<year>2005</year>). <article-title>3,4-N-methlenedioxymethamphetamine-induced hypophagia is maintained in 5-HT1B receptor knockout mice, but suppressed by the 5-HT2C receptor antagonist RS102221.</article-title>
<source/><italic>Neuropsychopharmacology</italic>
<volume>30</volume>
<fpage>1056</fpage>–<lpage>1063</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1300662</pub-id>
<pub-id pub-id-type="pmid">15668722</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crespi</surname><given-names>D.</given-names></name><name><surname>Mennini</surname><given-names>T.</given-names></name><name><surname>Gobbi</surname><given-names>M.</given-names></name></person-group> (<year>1997</year>). <article-title>Carrier-dependent and Ca<sup>2+</sup>-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine.</article-title>
<source/><italic>Br. J. Pharmacol.</italic>
<volume>121</volume>
<fpage>1735</fpage>–<lpage>1743</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0701325</pub-id>
<pub-id pub-id-type="pmid">9283711</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de la Torre-Ubieta</surname><given-names>L.</given-names></name><name><surname>Won</surname><given-names>H.</given-names></name><name><surname>Stein</surname><given-names>J. L.</given-names></name><name><surname>Geschwind</surname><given-names>D. H.</given-names></name></person-group> (<year>2016</year>). <article-title>Advancing the understanding of autism disease mechanisms through genetics.</article-title>
<source/><italic>Nat. Med.</italic>
<volume>22</volume>
<fpage>345</fpage>–<lpage>361</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4071</pub-id>
<pub-id pub-id-type="pmid">27050589</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denayer</surname><given-names>A.</given-names></name><name><surname>van Esch</surname><given-names>H.</given-names></name><name><surname>de Ravel</surname><given-names>T.</given-names></name><name><surname>Frijns</surname><given-names>J. P.</given-names></name><name><surname>van Buggenhout</surname><given-names>G.</given-names></name><name><surname>Vogels</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Neuropsychopathology in 7 patients with the 22q13 deletion syndrome: presence of bipolar disorder and progressive loss of skills.</article-title>
<source/><italic>Mol. Syndromol.</italic>
<volume>3</volume>
<fpage>14</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1159/000339119</pub-id>
<pub-id pub-id-type="pmid">22855650</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>J. V.</given-names></name><name><surname>Rodriguiz</surname><given-names>R. M.</given-names></name><name><surname>Hutchinson</surname><given-names>A. N.</given-names></name><name><surname>Kim</surname><given-names>I. H.</given-names></name><name><surname>Wetsel</surname><given-names>W. C.</given-names></name><name><surname>West</surname><given-names>A. E.</given-names></name></person-group> (<year>2010</year>). <article-title>MeCP2 in the nucleus accumbens contributes to neural and behavioral responses to psychostimulants.</article-title>
<source/><italic>Nat. Neurosci.</italic>
<volume>13</volume>
<fpage>1128</fpage>–<lpage>1136</lpage>. <pub-id pub-id-type="doi">10.1038/nn.2614</pub-id>
<pub-id pub-id-type="pmid">20711186</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dluzen</surname><given-names>D. E.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Story</surname><given-names>G. M.</given-names></name><name><surname>Anderson</surname><given-names>L. I.</given-names></name><name><surname>Kucera</surname><given-names>J.</given-names></name><name><surname>Walro</surname><given-names>J. M.</given-names></name></person-group> (<year>2001</year>). <article-title>Evaluation of nigrostriatal dopaminergic function in adult +/+ and +/- BDNF mutant mice.</article-title>
<source/><italic>Exp. Neurol.</italic>
<volume>170</volume>
<fpage>121</fpage>–<lpage>128</lpage>. <pub-id pub-id-type="doi">10.1006/exnr.2001.7698</pub-id>
<pub-id pub-id-type="pmid">11421589</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doly</surname><given-names>S.</given-names></name><name><surname>Bertran-Gonzalez</surname><given-names>J.</given-names></name><name><surname>Callebert</surname><given-names>J.</given-names></name><name><surname>Bruneau</surname><given-names>A.</given-names></name><name><surname>Banas</surname><given-names>S. M.</given-names></name><name><surname>Belmer</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Role of serotonin via 5-HT2B receptors in the reinforcing effects of MDMA in mice.</article-title>
<source/><italic>PLoS One</italic>
<volume>4</volume>:<issue>e7952</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0007952</pub-id>
<pub-id pub-id-type="pmid">19956756</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doly</surname><given-names>S.</given-names></name><name><surname>Valjent</surname><given-names>E.</given-names></name><name><surname>Setola</surname><given-names>V.</given-names></name><name><surname>Callebert</surname><given-names>J.</given-names></name><name><surname>Hervé</surname><given-names>D.</given-names></name><name><surname>Launay</surname><given-names>J. M.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>28</volume>
<fpage>2933</fpage>–<lpage>2940</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5723-07.2008</pub-id>
<pub-id pub-id-type="pmid">18337424</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>F.</given-names></name><name><surname>Nguyen</surname><given-names>M. V.</given-names></name><name><surname>Karten</surname><given-names>A.</given-names></name><name><surname>Felice</surname><given-names>C. A.</given-names></name><name><surname>Mandel</surname><given-names>G.</given-names></name><name><surname>Ballas</surname><given-names>N.</given-names></name></person-group> (<year>2016</year>). <article-title>Acute and crucial requirement for MeCP2 function upon transition from early to late adult stages of brain maturation.</article-title>
<source/><italic>Hum. Mol. Genet.</italic>
<volume>25</volume>
<fpage>1690</fpage>–<lpage>1702</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddw038</pub-id>
<pub-id pub-id-type="pmid">26908602</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durand</surname><given-names>C. M.</given-names></name><name><surname>Betancur</surname><given-names>C.</given-names></name><name><surname>Boeckers</surname><given-names>T. M.</given-names></name><name><surname>Bockmann</surname><given-names>J.</given-names></name><name><surname>Chaste</surname><given-names>P.</given-names></name><name><surname>Fauchereau</surname><given-names>F.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders.</article-title>
<source/><italic>Nat. Genet.</italic>
<volume>39</volume>
<fpage>25</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1038/ng1933</pub-id>
<pub-id pub-id-type="pmid">17173049</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erhardt</surname><given-names>S.</given-names></name><name><surname>Schwieler</surname><given-names>L.</given-names></name><name><surname>Imbeault</surname><given-names>S.</given-names></name><name><surname>Engberg</surname><given-names>G.</given-names></name></person-group> (<year>2017</year>). <article-title>The kynurenine pathway in schizophrenia and bipolar disorder.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>112</volume>
<fpage>297</fpage>–<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2016.05.020</pub-id>
<pub-id pub-id-type="pmid">27245499</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Everitt</surname><given-names>B. J.</given-names></name><name><surname>Robbins</surname><given-names>T. W.</given-names></name></person-group> (<year>2016</year>). <article-title>Drug addiction: updating actions to habits to compulsions ten years on.</article-title>
<source/><italic>Annu. Rev. Psychol.</italic>
<volume>67</volume>
<fpage>23</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-psych-122414-033457</pub-id>
<pub-id pub-id-type="pmid">26253543</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ey</surname><given-names>E.</given-names></name><name><surname>Torquet</surname><given-names>T.</given-names></name><name><surname>de Chaumont</surname><given-names>F.</given-names></name><name><surname>Lévi-Strauss</surname><given-names>J.</given-names></name><name><surname>Ferhat</surname><given-names>A. T.</given-names></name><name><surname>Le Sourd</surname><given-names>A. M.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>SHANK2 mutant mice display hyperactivity insensitive to methylphenidate and reduced flexibility in social motivation, but normal social recognition.</article-title>
<source/><italic>Front. Mol. Neurosci.</italic>
<volume>11</volume>:<issue>365</issue>. <pub-id pub-id-type="doi">10.3389/fnmol.2018.00365</pub-id>
<pub-id pub-id-type="pmid">30337855</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>X.</given-names></name><name><surname>Hess</surname><given-names>E. J.</given-names></name></person-group> (<year>2007</year>). <article-title>D2-like dopamine receptors mediate the response to amphetamine in a mouse model of ADHD.</article-title>
<source/><italic>Neurobiol. Dis.</italic>
<volume>26</volume>
<fpage>201</fpage>–<lpage>211</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2006.12.011</pub-id>
<pub-id pub-id-type="pmid">17291774</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Hess</surname><given-names>E. J.</given-names></name></person-group> (<year>2010</year>). <article-title>D2 dopamine receptor subtype-mediated hyperactivity and amphetamine responses in a model of ADHD.</article-title>
<source/><italic>Neurobiol. Dis.</italic>
<volume>37</volume>
<fpage>228</fpage>–<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2009.10.009</pub-id>
<pub-id pub-id-type="pmid">19840852</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fantegrossi</surname><given-names>W. E.</given-names></name><name><surname>Godlewski</surname><given-names>T.</given-names></name><name><surname>Karabenick</surname><given-names>R. L.</given-names></name><name><surname>Stephens</surname><given-names>J. M.</given-names></name><name><surname>Ullrich</surname><given-names>T.</given-names></name><name><surname>Rice</surname><given-names>K. C.</given-names></name><etal></etal></person-group> (<year>2003</year>). <article-title>Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine (“ecstasy”) and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice.</article-title>
<source/><italic>Psychopharmacology</italic>
<volume>166</volume>
<fpage>202</fpage>–<lpage>211</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-002-1261-5</pub-id>
<pub-id pub-id-type="pmid">12563544</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filice</surname><given-names>F.</given-names></name><name><surname>Vörckel</surname><given-names>K. J.</given-names></name><name><surname>Sungur</surname><given-names>A. Ö.</given-names></name><name><surname>Wöhr</surname><given-names>M.</given-names></name><name><surname>Schwaller</surname><given-names>B.</given-names></name></person-group> (<year>2016</year>). <article-title>Reduction in parvalbumin expression not loss of the parvalbumin-expressing GABA interneuron subpopulation in genetic parvalbumin and shank mouse models of autism.</article-title>
<source/><italic>Mol. Brain</italic>
<volume>9</volume>:<issue>e10</issue>. <pub-id pub-id-type="doi">10.1186/s13041-016-0192-8</pub-id>
<pub-id pub-id-type="pmid">26819149</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fromer</surname><given-names>M.</given-names></name><name><surname>Pocklington</surname><given-names>A. J.</given-names></name><name><surname>Kavanagh</surname><given-names>D. H.</given-names></name><name><surname>Williams</surname><given-names>H. J.</given-names></name><name><surname>Dwyer</surname><given-names>S.</given-names></name><name><surname>Gormley</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>De novo mutations in schizophrenia implicate synaptic networks.</article-title>
<source/><italic>Nature</italic>
<volume>506</volume>
<fpage>179</fpage>–<lpage>184</lpage>. <pub-id pub-id-type="doi">10.1038/nature12929</pub-id>
<pub-id pub-id-type="pmid">24463507</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gainetdinov</surname><given-names>R. R.</given-names></name><name><surname>Wetsel</surname><given-names>W. C.</given-names></name><name><surname>Jones</surname><given-names>S. R.</given-names></name><name><surname>Levin</surname><given-names>E. D.</given-names></name><name><surname>Jaber</surname><given-names>M.</given-names></name><name><surname>Caron</surname><given-names>M. G.</given-names></name></person-group> (<year>1999</year>). <article-title>Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity.</article-title>
<source/><italic>Science</italic>
<volume>283</volume>
<fpage>397</fpage>–<lpage>401</lpage>. <pub-id pub-id-type="doi">10.1126/science.283.5400.397</pub-id><pub-id pub-id-type="pmid">9888856</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García-Pardo</surname><given-names>M. P.</given-names></name><name><surname>Escobar-Valero</surname><given-names>C.</given-names></name><name><surname>Rodríguez-Arias</surname><given-names>M.</given-names></name><name><surname>Miñarro</surname><given-names>J.</given-names></name><name><surname>Aguilar</surname><given-names>M. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Involvement of NMDA glutamate receptors in the acquisition and reinstatement of the conditioned place preference induced by MDMA.</article-title>
<source/><italic>Behav. Pharmacol.</italic>
<volume>26</volume>
<fpage>411</fpage>–<lpage>417</lpage>. <pub-id pub-id-type="doi">10.1097/FBP.0000000000000138</pub-id>
<pub-id pub-id-type="pmid">25974188</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García-Pardo</surname><given-names>M. P.</given-names></name><name><surname>Miñarro</surname><given-names>J.</given-names></name><name><surname>Aguilar</surname><given-names>M. A.</given-names></name></person-group> (<year>2018</year>). <article-title>Role of AMPA glutamate receptors in the conditioned rewarding effects of MDMA in mice.</article-title>
<source/><italic>Behav. Brain Res.</italic>
<volume>347</volume>
<fpage>57</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2018.03.010</pub-id>
<pub-id pub-id-type="pmid">29526785</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gauthier</surname><given-names>J.</given-names></name><name><surname>Champagne</surname><given-names>N.</given-names></name><name><surname>Lafrenière</surname><given-names>R. G.</given-names></name><name><surname>Xiong</surname><given-names>L.</given-names></name><name><surname>Spiegelman</surname><given-names>D.</given-names></name><name><surname>Brustein</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>107</volume>
<fpage>7863</fpage>–<lpage>7868</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0906232107</pub-id>
<pub-id pub-id-type="pmid">20385823</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gauthier</surname><given-names>J.</given-names></name><name><surname>Spiegelman</surname><given-names>D.</given-names></name><name><surname>Piton</surname><given-names>A.</given-names></name><name><surname>Lafrenière</surname><given-names>R. G.</given-names></name><name><surname>Laurent</surname><given-names>S.</given-names></name><name><surname>St-Onge</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Novel de novo SHANK3 mutation in autistic patients.</article-title>
<source/><italic>Am. J. Med. Genet. Part B Neuropsychiatr. Genet.</italic>
<volume>150B</volume>
<fpage>421</fpage>–<lpage>424</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.b.30822</pub-id>
<pub-id pub-id-type="pmid">18615476</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geoffroy</surname><given-names>P. A.</given-names></name><name><surname>Etain</surname><given-names>B.</given-names></name><name><surname>Franchi</surname><given-names>J. A.</given-names></name><name><surname>Bellivier</surname><given-names>F.</given-names></name><name><surname>Ritter</surname><given-names>P.</given-names></name></person-group> (<year>2015</year>). <article-title>Melatonin and melatonin agonists as adjunctive treatments in bipolar disorders.</article-title>
<source/><italic>Curr. Pharm. Des.</italic>
<volume>21</volume>
<fpage>3352</fpage>–<lpage>3358</lpage>. <pub-id pub-id-type="doi">10.2174/1381612821666150619093448</pub-id><pub-id pub-id-type="pmid">26088111</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geschwind</surname><given-names>D. H.</given-names></name><name><surname>Flint</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>Genetics and genomics of psychiatric disease.</article-title>
<source/><italic>Science</italic>
<volume>349</volume>
<fpage>1489</fpage>–<lpage>1494</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaa8954</pub-id>
<pub-id pub-id-type="pmid">26404826</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giros</surname><given-names>B.</given-names></name><name><surname>Jaber</surname><given-names>M.</given-names></name><name><surname>Jones</surname><given-names>S. R.</given-names></name><name><surname>Wightman</surname><given-names>R. M.</given-names></name><name><surname>Caron</surname><given-names>M. G.</given-names></name></person-group> (<year>1996</year>). <article-title>Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter.</article-title>
<source/><italic>Nature</italic>
<volume>379</volume>
<fpage>606</fpage>–<lpage>612</lpage>. <pub-id pub-id-type="doi">10.1038/379606a0</pub-id>
<pub-id pub-id-type="pmid">8628395</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gould</surname><given-names>T. J.</given-names></name><name><surname>Keith</surname><given-names>R. A.</given-names></name><name><surname>Bhat</surname><given-names>R. V.</given-names></name></person-group> (<year>2001</year>). <article-title>Differential sensitivity to lithium’s reversal of amphetamine-induced open-field activity in two inbred strains of mice.</article-title>
<source/><italic>Behav. Brain Res.</italic>
<volume>118</volume>
<fpage>95</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1016/S0166-4328(00)00318-1</pub-id><pub-id pub-id-type="pmid">11163638</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillin</surname><given-names>O.</given-names></name><name><surname>Diaz</surname><given-names>J.</given-names></name><name><surname>Carroll</surname><given-names>P.</given-names></name><name><surname>Griffon</surname><given-names>N.</given-names></name><name><surname>Schwartz</surname><given-names>J. C.</given-names></name><name><surname>Sokoloff</surname><given-names>P.</given-names></name></person-group> (<year>2001</year>). <article-title>BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization.</article-title>
<source/><italic>Nature</italic>
<volume>411</volume>
<fpage>86</fpage>–<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1038/35075076</pub-id>
<pub-id pub-id-type="pmid">11333982</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guilmatre</surname><given-names>A.</given-names></name><name><surname>Huguet</surname><given-names>G.</given-names></name><name><surname>Delorme</surname><given-names>R.</given-names></name><name><surname>Bourgeron</surname><given-names>T.</given-names></name></person-group> (<year>2014</year>). <article-title>The emerging role of SHANK genes in neuropsychiatric disorders.</article-title>
<source/><italic>Dev. Neurobiol.</italic>
<volume>74</volume>
<fpage>113</fpage>–<lpage>122</lpage>. <pub-id pub-id-type="doi">10.1002/dneu.22128</pub-id>
<pub-id pub-id-type="pmid">24124131</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>K.</given-names></name><name><surname>Holder</surname><given-names>J. L.</given-names><suffix>Jr.</suffix></name><name><surname>Schaaf</surname><given-names>C. P.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Kang</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties.</article-title>
<source/><italic>Nature</italic>
<volume>503</volume>
<fpage>72</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1038/nature12630</pub-id>
<pub-id pub-id-type="pmid">24153177</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasler</surname><given-names>G.</given-names></name><name><surname>Drevets</surname><given-names>W. C.</given-names></name><name><surname>Gould</surname><given-names>T. D.</given-names></name><name><surname>Gottesman</surname><given-names>I. I.</given-names></name><name><surname>Manji</surname><given-names>H. K.</given-names></name></person-group> (<year>2006</year>). <article-title>Toward constructing an endophenotype strategy for bipolar disorders.</article-title>
<source/><italic>Biol. Psychiatry</italic>
<volume>60</volume>
<fpage>93</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2005.11.006</pub-id>
<pub-id pub-id-type="pmid">16406007</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homann</surname><given-names>O. R.</given-names></name><name><surname>Misura</surname><given-names>K.</given-names></name><name><surname>Lamas</surname><given-names>E.</given-names></name><name><surname>Sandrock</surname><given-names>R. W.</given-names></name><name><surname>Nelson</surname><given-names>P.</given-names></name><name><surname>McDonough</surname><given-names>S. I.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Whole-genome sequencing in multiplex families with psychoses reveals mutations in the SHANK2 and SMARCA1 genes segregating with illness.</article-title>
<source/><italic>Mol. Psychiatry</italic>
<volume>21</volume>
<fpage>1690</fpage>–<lpage>1695</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2016.24</pub-id>
<pub-id pub-id-type="pmid">27001614</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Gan</surname><given-names>J.</given-names></name><name><surname>Jonas</surname><given-names>P.</given-names></name></person-group> (<year>2014</year>). <article-title>Interneurons. Fast-spiking, parvalbumin<sup>+</sup> GABAergic interneurons: from cellular design to microcircuit function.</article-title>
<source/><italic>Science</italic>
<volume>345</volume>:<issue>1255263</issue>. <pub-id pub-id-type="doi">10.1126/science.1255263</pub-id>
<pub-id pub-id-type="pmid">25082707</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>A. Y.</given-names></name><name><surname>Futai</surname><given-names>K.</given-names></name><name><surname>Sala</surname><given-names>C.</given-names></name><name><surname>Valtschanoff</surname><given-names>J. G.</given-names></name><name><surname>Ryu</surname><given-names>J.</given-names></name><name><surname>Woodworth</surname><given-names>M. A.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Smaller dendritic spines, weaker synaptic transmission, but enhanced spatial learning in mice lacking SHANK1.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>28</volume>
<fpage>1697</fpage>–<lpage>1708</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3032-07.2008</pub-id>
<pub-id pub-id-type="pmid">18272690</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutson</surname><given-names>P. H.</given-names></name><name><surname>Tarazi</surname><given-names>F. I.</given-names></name><name><surname>Madhoo</surname><given-names>M.</given-names></name><name><surname>Slawecki</surname><given-names>C.</given-names></name><name><surname>Patkar</surname><given-names>A. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Preclinical pharmacology of amphetamine: implications for the treatment of neuropsychiatric disorders.</article-title>
<source/><italic>Pharmacol. Ther.</italic>
<volume>143</volume>
<fpage>253</fpage>–<lpage>264</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2014.03.005</pub-id>
<pub-id pub-id-type="pmid">24657455</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jean</surname><given-names>A.</given-names></name><name><surname>Laurent</surname><given-names>L.</given-names></name><name><surname>Bockaert</surname><given-names>J.</given-names></name><name><surname>Charnay</surname><given-names>Y.</given-names></name><name><surname>Dusticier</surname><given-names>N.</given-names></name><name><surname>Nieoullon</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>The nucleus accumbens 5-HTR<sub>4</sub>-CART pathway ties anorexia to hyperactivity.</article-title>
<source/><italic>Transl. Psychiatry</italic>
<volume>2</volume>:<issue>e203</issue>. <pub-id pub-id-type="doi">10.1038/tp.2012.131</pub-id>
<pub-id pub-id-type="pmid">23233022</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Ehlers</surname><given-names>M. D.</given-names></name></person-group> (<year>2013</year>). <article-title>Modeling autism by SHANK gene mutations in mice.</article-title>
<source/><italic>Neuron</italic>
<volume>78</volume>
<fpage>8</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2013.03.016</pub-id>
<pub-id pub-id-type="pmid">23583105</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>T.</given-names></name><name><surname>Kubota</surname><given-names>M.</given-names></name><name><surname>Kasahara</surname><given-names>T.</given-names></name></person-group> (<year>2007</year>). <article-title>Animal models of bipolar disorder.</article-title>
<source/><italic>Neurosci. Biobehav. Rev.</italic>
<volume>31</volume>
<fpage>832</fpage>–<lpage>842</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2007.03.003</pub-id>
<pub-id pub-id-type="pmid">17466374</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lennertz</surname><given-names>L.</given-names></name><name><surname>Wagner</surname><given-names>M.</given-names></name><name><surname>Wölwer</surname><given-names>W.</given-names></name><name><surname>Schuhmacher</surname><given-names>A.</given-names></name><name><surname>Frommann</surname><given-names>I.</given-names></name><name><surname>Berning</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>A promoter variant of SHANK1 affects auditory working memory in schizophrenia patients and in subjects clinically at risk for psychosis.</article-title>
<source/><italic>Eur. Arch. Psychiatry Clin. Neurosci.</italic>
<volume>262</volume>
<fpage>117</fpage>–<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1007/s00406-011-0233-3</pub-id>
<pub-id pub-id-type="pmid">21901269</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Abdourahman</surname><given-names>A.</given-names></name><name><surname>Tamm</surname><given-names>J. A.</given-names></name><name><surname>Pehrson</surname><given-names>A. L.</given-names></name><name><surname>Sánchez</surname><given-names>C.</given-names></name><name><surname>Gulinello</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Reversal of age-associated cognitive deficits is accompanied by increased plasticity-related gene expression after chronic antidepressant administration in middle-aged mice.</article-title>
<source/><italic>Pharmacol. Biochem. Behav.</italic>
<volume>135</volume>
<fpage>70</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2015.05.013</pub-id>
<pub-id pub-id-type="pmid">26046533</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>C. K.</given-names></name><name><surname>Essa</surname><given-names>M. M.</given-names></name><name><surname>de Paula Martins</surname><given-names>R.</given-names></name><name><surname>Lovejoy</surname><given-names>D. B.</given-names></name><name><surname>Bilgin</surname><given-names>A. A.</given-names></name><name><surname>Waly</surname><given-names>M. I.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Altered kynurenine pathway metabolism in autism: implication for immune-induced glutamatergic activity.</article-title>
<source/><italic>Autism Res.</italic>
<volume>9</volume>
<fpage>621</fpage>–<lpage>631</lpage>. <pub-id pub-id-type="doi">10.1002/aur.1565</pub-id>
<pub-id pub-id-type="pmid">26497015</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manning</surname><given-names>E. E.</given-names></name><name><surname>Halberstadt</surname><given-names>A. L.</given-names></name><name><surname>van den Buuse</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>BDNF-deficient mice show reduced psychosis-related behaviors following chronic methamphetamine.</article-title>
<source/><italic>Int. J. Neuropsychopharmacol.</italic>
<volume>19</volume>:<issue>yv116</issue>. <pub-id pub-id-type="doi">10.1093/ijnp/pyv116</pub-id>
<pub-id pub-id-type="pmid">26453694</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>W.</given-names></name><name><surname>Watanabe</surname><given-names>T.</given-names></name><name><surname>Cho</surname><given-names>S.</given-names></name><name><surname>Frost</surname><given-names>J. L.</given-names></name><name><surname>Truong</surname><given-names>T.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>SHANK1 regulates excitatory synaptic transmission in mouse hippocampal parvalbumin-expressing inhibitory interneurons.</article-title>
<source/><italic>Eur. J. Neurosci.</italic>
<volume>41</volume>
<fpage>1025</fpage>–<lpage>1035</lpage>. <pub-id pub-id-type="doi">10.1111/ejn.12877</pub-id>
<pub-id pub-id-type="pmid">25816842</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marín</surname><given-names>O.</given-names></name></person-group> (<year>2012</year>). <article-title>Interneuron dysfunction in psychiatric disorders.</article-title>
<source/><italic>Nat. Rev. Neurosci.</italic>
<volume>13</volume>
<fpage>107</fpage>–<lpage>120</lpage>. <pub-id pub-id-type="doi">10.1038/nrn3155</pub-id>
<pub-id pub-id-type="pmid">22251963</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marquis</surname><given-names>K. L.</given-names></name><name><surname>Sabb</surname><given-names>A. L.</given-names></name><name><surname>Logue</surname><given-names>S. F.</given-names></name><name><surname>Brennan</surname><given-names>J. A.</given-names></name><name><surname>Piesla</surname><given-names>M. J.</given-names></name><name><surname>Comery</surname><given-names>T. A.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino [6,7,1hi]indole]: a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.</article-title>
<source/><italic>J. Pharmacol. Exp. Ther.</italic>
<volume>320</volume>
<fpage>486</fpage>–<lpage>496</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.106.106989</pub-id>
<pub-id pub-id-type="pmid">17038512</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNamara</surname><given-names>R. K.</given-names></name><name><surname>Logue</surname><given-names>A.</given-names></name><name><surname>Stanford</surname><given-names>K.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Richtand</surname><given-names>N. M.</given-names></name></person-group> (<year>2006</year>). <article-title>Dose-response analysis of locomotor activity and stereotypy in dopamine D3 receptor mutant mice following acute amphetamine.</article-title>
<source/><italic>Synapse</italic>
<volume>60</volume>
<fpage>399</fpage>–<lpage>405</lpage>. <pub-id pub-id-type="doi">10.1002/syn.20315</pub-id>
<pub-id pub-id-type="pmid">16856172</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyendorff</surname><given-names>E.</given-names></name><name><surname>Lerer</surname><given-names>B.</given-names></name><name><surname>Moore</surname><given-names>N. C.</given-names></name><name><surname>Bow</surname><given-names>J.</given-names></name><name><surname>Gershon</surname><given-names>S.</given-names></name></person-group> (<year>1985</year>). <article-title>Methylphenidate infusion in euthymic bipolars: effect of carbamazepine pretreatment.</article-title>
<source/><italic>Psychiatry Res.</italic>
<volume>16</volume>
<fpage>303</fpage>–<lpage>308</lpage>. <pub-id pub-id-type="doi">10.1016/0165-1781(85)90121-0</pub-id>
<pub-id pub-id-type="pmid">4089058</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moessner</surname><given-names>R.</given-names></name><name><surname>Marshall</surname><given-names>C. R.</given-names></name><name><surname>Sutcliffe</surname><given-names>J. S.</given-names></name><name><surname>Skaug</surname><given-names>J.</given-names></name><name><surname>Pinto</surname><given-names>D.</given-names></name><name><surname>Vincent</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Contribution of SHANK3 mutations to autism spectrum disorder.</article-title>
<source/><italic>Am. J. Hum. Genet.</italic>
<volume>81</volume>
<fpage>1289</fpage>–<lpage>1297</lpage>. <pub-id pub-id-type="doi">10.1086/522590</pub-id>
<pub-id pub-id-type="pmid">17999366</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morera-Fumero</surname><given-names>A. L.</given-names></name><name><surname>Abreu-Gonzalez</surname><given-names>P.</given-names></name></person-group> (<year>2013</year>). <article-title>Role of melatonin in schizophrenia.</article-title>
<source/><italic>Int. J. Mol. Sci.</italic>
<volume>14</volume>
<fpage>9037</fpage>–<lpage>9050</lpage>. <pub-id pub-id-type="doi">10.3390/ijms14059037</pub-id>
<pub-id pub-id-type="pmid">23698762</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouri</surname><given-names>A.</given-names></name><name><surname>Noda</surname><given-names>Y.</given-names></name><name><surname>Niwa</surname><given-names>M.</given-names></name><name><surname>Matsumoto</surname><given-names>Y.</given-names></name><name><surname>Mamiya</surname><given-names>T.</given-names></name><name><surname>Nitta</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>The involvement of brain-derived neurotrophic factor in 3,4-methylenedioxymethamphetamine-induced place preference and behavioral sensitization.</article-title>
<source/><italic>Behav. Brain Res.</italic>
<volume>329</volume>
<fpage>157</fpage>–<lpage>165</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2017.04.052</pub-id>
<pub-id pub-id-type="pmid">28472632</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>C. P.</given-names></name><name><surname>Homberg</surname><given-names>J. R.</given-names></name></person-group> (<year>2015</year>). <article-title>The role of serotonin in drug use and addiction.</article-title>
<source/><italic>Behav. Brain Res.</italic>
<volume>277</volume>
<fpage>146</fpage>–<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2014.04.007</pub-id>
<pub-id pub-id-type="pmid">24769172</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natusch</surname><given-names>C.</given-names></name><name><surname>Schwarting</surname><given-names>R. K. W.</given-names></name></person-group> (<year>2010</year>). <article-title>Using bedding in a test environment critically affects 50-kHz ultrasonic vocalizations in laboratory rats.</article-title>
<source/><italic>Pharmacol. Biochem. Behav.</italic>
<volume>96</volume>
<fpage>251</fpage>–<lpage>259</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2010.05.013</pub-id>
<pub-id pub-id-type="pmid">20493210</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noor</surname><given-names>A.</given-names></name><name><surname>Lionel</surname><given-names>A. C.</given-names></name><name><surname>Cohen-Woods</surname><given-names>S.</given-names></name><name><surname>Moghimi</surname><given-names>N.</given-names></name><name><surname>Rucker</surname><given-names>J.</given-names></name><name><surname>Fennell</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Copy number variant study of bipolar disorder in Canadian and UK populations implicates synaptic genes.</article-title>
<source/><italic>Am. J. Med. Genet. B Neuropsychiatr. Genet.</italic>
<volume>165B</volume>
<fpage>303</fpage>–<lpage>313</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.b.32232</pub-id>
<pub-id pub-id-type="pmid">24700553</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Donovan</surname><given-names>M. C.</given-names></name><name><surname>Owen</surname><given-names>M. J.</given-names></name></person-group> (<year>2016</year>). <article-title>The implications of the shared genetics of psychiatric disorders.</article-title>
<source/><italic>Nat. Med.</italic>
<volume>22</volume>
<fpage>1214</fpage>–<lpage>1219</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4196</pub-id>
<pub-id pub-id-type="pmid">27783064</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Neill</surname><given-names>M. F.</given-names></name><name><surname>Heron-Maxwell</surname><given-names>C. L.</given-names></name><name><surname>Shaw</surname><given-names>G.</given-names></name></person-group> (<year>1999</year>). <article-title>5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB.</article-title>
<source/><italic>Pharmacol. Biochem. Behav.</italic>
<volume>63</volume>
<fpage>237</fpage>–<lpage>243</lpage>. <pub-id pub-id-type="doi">10.1016/S0091-3057(98)00240-8</pub-id>
<pub-id pub-id-type="pmid">10371652</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orejarena</surname><given-names>M. J.</given-names></name><name><surname>Lanfumey</surname><given-names>L.</given-names></name><name><surname>Maldonado</surname><given-names>R.</given-names></name><name><surname>Robledo</surname><given-names>P.</given-names></name></person-group> (<year>2011</year>). <article-title>Involvement of 5-HT2A receptors in MDMA reinforcement and cue-induced reinstatement of MDMA-seeking behaviour.</article-title>
<source/><italic>Int. J. Neuropsychopharmacol.</italic>
<volume>14</volume>
<fpage>927</fpage>–<lpage>940</lpage>. <pub-id pub-id-type="doi">10.1017/S1461145710001215</pub-id>
<pub-id pub-id-type="pmid">20942998</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>A.</given-names></name><name><surname>Das</surname><given-names>S.</given-names></name></person-group> (<year>2013</year>). <article-title>Chronic morphine exposure and its abstinence alters dendritic spine morphology and upregulates SHANK1.</article-title>
<source/><italic>Neurochem. Int.</italic>
<volume>62</volume>
<fpage>956</fpage>–<lpage>964</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2013.03.011</pub-id>
<pub-id pub-id-type="pmid">23538264</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pappas</surname><given-names>A. L.</given-names></name><name><surname>Bey</surname><given-names>A. L.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Rossi</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>Y. H.</given-names></name><name><surname>Yan</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Deficiency of SHANK2 causes mania-like behavior that responds to mood stabilizers.</article-title>
<source/><italic>JCI Insight</italic>
<pub-id pub-id-type="doi">10.1172/jci.insight.92052</pub-id>
<comment>[Epub ahead of print]</comment>. <pub-id pub-id-type="pmid">29046483</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Paxinos</surname><given-names>G.</given-names></name><name><surname>Franklin</surname><given-names>K. B. J.</given-names></name></person-group> (<year>2001</year>). <source/><italic>The Mouse Brain in Stereotaxic Coordinates</italic>
<edition>2nd Edn.</edition>
<publisher-loc>San Diego, CA</publisher-loc>: <publisher-name>Academic Press</publisher-name>.</mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peça</surname><given-names>J.</given-names></name><name><surname>Feliciano</surname><given-names>C.</given-names></name><name><surname>Ting</surname><given-names>J. T.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Wells</surname><given-names>M. F.</given-names></name><name><surname>Venkatraman</surname><given-names>T. N.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>SHANK3 mutant mice display autistic-like behaviours and striatal dysfunction.</article-title>
<source/><italic>Nature</italic>
<volume>472</volume>
<fpage>437</fpage>–<lpage>442</lpage>. <pub-id pub-id-type="doi">10.1038/nature09965</pub-id>
<pub-id pub-id-type="pmid">21423165</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peet</surname><given-names>M.</given-names></name><name><surname>Peters</surname><given-names>S.</given-names></name></person-group> (<year>1995</year>). <article-title>Drug-induced mania.</article-title>
<source/><italic>Drug Saf.</italic>
<volume>12</volume>
<fpage>146</fpage>–<lpage>153</lpage>. <pub-id pub-id-type="doi">10.2165/00002018-199512020-00007</pub-id>
<pub-id pub-id-type="pmid">7766338</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>M.</given-names></name><name><surname>Andreatini</surname><given-names>R.</given-names></name><name><surname>Schwarting</surname><given-names>R. K. W.</given-names></name><name><surname>Brenes</surname><given-names>J. C.</given-names></name></person-group> (<year>2014</year>). <article-title>Amphetamine-induced appetitive 50-kHz calls in rats: a marker of affect in mania?</article-title>
<source/><italic>Psychopharmacology</italic>
<volume>231</volume>
<fpage>2567</fpage>–<lpage>2577</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-013-3413-1</pub-id>
<pub-id pub-id-type="pmid">24414610</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peykov</surname><given-names>S.</given-names></name><name><surname>Berkel</surname><given-names>S.</given-names></name><name><surname>Schoen</surname><given-names>M.</given-names></name><name><surname>Weiss</surname><given-names>K.</given-names></name><name><surname>Degenhardt</surname><given-names>F.</given-names></name><name><surname>Strohmaier</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Identification and functional characterization of rare SHANK2 variants in schizophrenia.</article-title>
<source/><italic>Mol. Psychiatry</italic>
<volume>20</volume>
<fpage>1489</fpage>–<lpage>1498</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2014.172</pub-id>
<pub-id pub-id-type="pmid">25560758</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>D.</given-names></name><name><surname>Pagnamenta</surname><given-names>A. T.</given-names></name><name><surname>Klei</surname><given-names>L.</given-names></name><name><surname>Anney</surname><given-names>R.</given-names></name><name><surname>Merico</surname><given-names>D.</given-names></name><name><surname>Regan</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Functional impact of global rare copy number variation in autism spectrum disorders.</article-title>
<source/><italic>Nature</italic>
<volume>466</volume>
<fpage>368</fpage>–<lpage>372</lpage>. <pub-id pub-id-type="doi">10.1038/nature09146</pub-id>
<pub-id pub-id-type="pmid">20531469</pub-id></mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>S. B.</given-names></name><name><surname>Lehmann-Masten</surname><given-names>V. D.</given-names></name><name><surname>Paulus</surname><given-names>M. P.</given-names></name><name><surname>Gainetdinov</surname><given-names>R. R.</given-names></name><name><surname>Caron</surname><given-names>M. G.</given-names></name><name><surname>Geyer</surname><given-names>M. A.</given-names></name></person-group> (<year>2004</year>). <article-title>MDMA “ecstasy” alters hyperactive and perseverative behaviors in dopamine transporter knockout mice.</article-title>
<source/><italic>Psychopharmacology</italic>
<volume>173</volume>
<fpage>310</fpage>–<lpage>317</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-003-1765-7</pub-id>
<pub-id pub-id-type="pmid">14747902</pub-id></mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przegalinski</surname><given-names>E.</given-names></name><name><surname>Siwanowicz</surname><given-names>J.</given-names></name><name><surname>Baran</surname><given-names>L.</given-names></name><name><surname>Filip</surname><given-names>M.</given-names></name></person-group> (<year>2000</year>). <article-title>Activation of serotonin (5-HT)1A receptors inhibits amphetamine sensitization in mice.</article-title>
<source/><italic>Life Sci.</italic>
<volume>66</volume>
<fpage>1011</fpage>–<lpage>1019</lpage>. <pub-id pub-id-type="doi">10.1016/S0024-3205(99)00666-9</pub-id>
<pub-id pub-id-type="pmid">10724448</pub-id></mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przegalinski</surname><given-names>E.</given-names></name><name><surname>Siwanowicz</surname><given-names>J.</given-names></name><name><surname>Nowak</surname><given-names>E.</given-names></name><name><surname>Papla</surname><given-names>I.</given-names></name><name><surname>Filip</surname><given-names>M.</given-names></name></person-group> (<year>2001</year>). <article-title>Role of 5-HT(1B) receptors in the sensitization to amphetamine in mice.</article-title>
<source/><italic>Eur. J. Pharmacol.</italic>
<volume>422</volume>
<fpage>91</fpage>–<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1016/S0014-2999(01)01079-2</pub-id><pub-id pub-id-type="pmid">11430919</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pum</surname><given-names>M.</given-names></name><name><surname>Carey</surname><given-names>R. J.</given-names></name><name><surname>Huston</surname><given-names>J. P.</given-names></name><name><surname>Müller</surname><given-names>C. P.</given-names></name></person-group> (<year>2007</year>). <article-title>Dissociating effects of cocaine and d-amphetamine on dopamine and serotonin in the perirhinal, entorhinal, and prefrontal cortex of freely moving rats.</article-title>
<source/><italic>Psychopharmacology</italic>
<volume>193</volume>
<fpage>375</fpage>–<lpage>390</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-007-0791-2</pub-id>
<pub-id pub-id-type="pmid">17468969</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Risbrough</surname><given-names>V. B.</given-names></name><name><surname>Masten</surname><given-names>V. L.</given-names></name><name><surname>Caldwell</surname><given-names>S.</given-names></name><name><surname>Paulus</surname><given-names>M. P.</given-names></name><name><surname>Low</surname><given-names>M. J.</given-names></name><name><surname>Geyer</surname><given-names>M. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice.</article-title>
<source/><italic>Neuropsychopharmacology</italic>
<volume>31</volume>
<fpage>2349</fpage>–<lpage>2358</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1301161</pub-id>
<pub-id pub-id-type="pmid">16855533</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roggero</surname><given-names>E.</given-names></name><name><surname>Pérez</surname><given-names>A. R.</given-names></name><name><surname>Pollachini</surname><given-names>N.</given-names></name><name><surname>Villar</surname><given-names>S. R.</given-names></name><name><surname>Wildmann</surname><given-names>J.</given-names></name><name><surname>Besedovsky</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>The sympathetic nervous system affects the susceptibility and course of <italic>Trypanosoma cruzi</italic> infection.</article-title>
<source/><italic>Brain Behav. Immun.</italic>
<volume>58</volume>
<fpage>228</fpage>–<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2016.07.163</pub-id>
<pub-id pub-id-type="pmid">27485039</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossignol</surname><given-names>D. A.</given-names></name><name><surname>Frye</surname><given-names>R. E.</given-names></name></person-group> (<year>2014</year>). <article-title>Melatonin in autism spectrum disorders.</article-title>
<source/><italic>Curr. Clin. Pharmacol.</italic>
<volume>9</volume>
<fpage>326</fpage>–<lpage>334</lpage>. <pub-id pub-id-type="doi">10.2174/15748847113086660072</pub-id><pub-id pub-id-type="pmid">24050742</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sala</surname><given-names>C.</given-names></name><name><surname>Vicidomini</surname><given-names>C.</given-names></name><name><surname>Bigi</surname><given-names>I.</given-names></name><name><surname>Mossa</surname><given-names>A.</given-names></name><name><surname>Verpelli</surname><given-names>C.</given-names></name></person-group> (<year>2015</year>). <article-title>Shank synaptic scaffold proteins: keys to understanding the pathogenesis of autism and other synaptic disorders.</article-title>
<source/><italic>J. Neurochem.</italic>
<volume>135</volume>
<fpage>849</fpage>–<lpage>858</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.13232</pub-id>
<pub-id pub-id-type="pmid">26338675</pub-id></mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salahpour</surname><given-names>A.</given-names></name><name><surname>Ramsey</surname><given-names>A. J.</given-names></name><name><surname>Medvedev</surname><given-names>I. O.</given-names></name><name><surname>Kile</surname><given-names>B.</given-names></name><name><surname>Sotnikova</surname><given-names>T. D.</given-names></name><name><surname>Holmstrand</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Increased amphetamine-induced hyperactivity and reward in mice overexpressing the dopamine transporter.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>105</volume>
<fpage>4405</fpage>–<lpage>4410</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0707646105</pub-id>
<pub-id pub-id-type="pmid">18347339</pub-id></mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salomon</surname><given-names>L.</given-names></name><name><surname>Lanteri</surname><given-names>C.</given-names></name><name><surname>Godeheu</surname><given-names>G.</given-names></name><name><surname>Blanc</surname><given-names>G.</given-names></name><name><surname>Gingrich</surname><given-names>J.</given-names></name><name><surname>Tassin</surname><given-names>J. P.</given-names></name></person-group> (<year>2007</year>). <article-title>Paradoxical constitutive behavioral sensitization to amphetamine in mice lacking 5-HT2A receptors.</article-title>
<source/><italic>Psychopharmacology</italic>
<volume>194</volume>
<fpage>11</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-007-0810-3</pub-id>
<pub-id pub-id-type="pmid">17510759</pub-id></mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>D.</given-names></name><name><surname>Lionel</surname><given-names>A. C.</given-names></name><name><surname>Leblond</surname><given-names>C. S.</given-names></name><name><surname>Prasad</surname><given-names>A.</given-names></name><name><surname>Pinto</surname><given-names>D.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>SHANK1 deletions in males with autism spectrum disorder.</article-title>
<source/><italic>Am. J. Hum. Genet.</italic>
<volume>90</volume>
<fpage>879</fpage>–<lpage>887</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2012.03.017</pub-id>
<pub-id pub-id-type="pmid">22503632</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saylor</surname><given-names>A. J.</given-names></name><name><surname>McGinty</surname><given-names>J. F.</given-names></name></person-group> (<year>2008</year>). <article-title>Amphetamine-induced locomotion and gene expression are altered in BDNF heterozygous mice.</article-title>
<source/><italic>Genes Brain Behav.</italic>
<volume>7</volume>
<fpage>906</fpage>–<lpage>914</lpage>. <pub-id pub-id-type="doi">10.1111/j.1601-183X.2008.00430.x</pub-id>
<pub-id pub-id-type="pmid">18681898</pub-id></mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scearce-Levie</surname><given-names>K.</given-names></name><name><surname>Viswanathan</surname><given-names>S. S.</given-names></name><name><surname>Hen</surname><given-names>R.</given-names></name></person-group> (<year>1999</year>). <article-title>Locomotor response to MDMA is attenuated in knockout mice lacking the 5-HT1B receptor.</article-title>
<source/><italic>Psychopharmacology</italic>
<volume>141</volume>
<fpage>154</fpage>–<lpage>161</lpage>. <pub-id pub-id-type="doi">10.1007/s002130050819</pub-id>
<pub-id pub-id-type="pmid">9952039</pub-id></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmeisser</surname><given-names>M. J.</given-names></name><name><surname>Ey</surname><given-names>E.</given-names></name><name><surname>Wegener</surname><given-names>S.</given-names></name><name><surname>Bockmann</surname><given-names>J.</given-names></name><name><surname>Stempel</surname><given-names>A. V.</given-names></name><name><surname>Kuebler</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Autistic-like behaviours and hyperactivity in mice lacking ProSAP1/SHANK2.</article-title>
<source/><italic>Nature</italic>
<volume>486</volume>
<fpage>256</fpage>–<lpage>260</lpage>. <pub-id pub-id-type="doi">10.1038/nature11015</pub-id>
<pub-id pub-id-type="pmid">22699619</pub-id></mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Schmeisser</surname><given-names>M. J.</given-names></name><name><surname>Verpelli</surname><given-names>C.</given-names></name></person-group> (<year>2016</year>). <article-title>“SHANK mutations in intellectual disability and autism spectrum disorder,” in</article-title>
<source/><italic>Neuronal and Synaptic Dysfunction in Autism Spectrum Disorder and Intellectual Disability</italic>
<role>eds</role>
<person-group person-group-type="editor"><name><surname>Sala</surname><given-names>C.</given-names></name><name><surname>Verpelli</surname><given-names>C.</given-names></name></person-group> (<publisher-loc>Cambridge, MA</publisher-loc>: <publisher-name>Academic Press</publisher-name>) <fpage>151</fpage>–<lpage>160</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-800109-7.00010-8</pub-id></mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>J. L.</given-names></name><name><surname>Turner</surname><given-names>S. M.</given-names></name><name><surname>Barkan</surname><given-names>C. L.</given-names></name><name><surname>Tolu</surname><given-names>S. S.</given-names></name><name><surname>Saxena</surname><given-names>R.</given-names></name><name><surname>Hung</surname><given-names>A. Y.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Sociability and motor functions in SHANK1 mutant mice.</article-title>
<source/><italic>Brain Res.</italic>
<volume>1380</volume>
<fpage>120</fpage>–<lpage>137</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2010.09.026</pub-id>
<pub-id pub-id-type="pmid">20868654</pub-id></mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>J. L.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Lord</surname><given-names>C.</given-names></name><name><surname>Crawley</surname><given-names>J. N.</given-names></name></person-group> (<year>2010</year>). <article-title>Behavioural phenotyping assays for mouse models of autism.</article-title>
<source/><italic>Nat. Rev. Neurosci.</italic>
<volume>11</volume>
<fpage>490</fpage>–<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2010.09.026</pub-id>
<pub-id pub-id-type="pmid">20559336</pub-id></mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorensen</surname><given-names>S. M.</given-names></name><name><surname>Kehne</surname><given-names>J. H.</given-names></name><name><surname>Fadayel</surname><given-names>G. M.</given-names></name><name><surname>Humphreys</surname><given-names>T. M.</given-names></name><name><surname>Ketteler</surname><given-names>H. J.</given-names></name><name><surname>Sullivan</surname><given-names>C. K.</given-names></name><etal></etal></person-group> (<year>1993</year>). <article-title>Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies.</article-title>
<source/><italic>J. Pharmacol. Exp. Ther.</italic>
<volume>266</volume>
<fpage>684</fpage>–<lpage>691</lpage>. <pub-id pub-id-type="pmid">8102646</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sovner</surname><given-names>R.</given-names></name><name><surname>Stone</surname><given-names>A.</given-names></name><name><surname>Fox</surname><given-names>C.</given-names></name></person-group> (<year>1996</year>). <article-title>Ring chromosome 22 and mood disorders.</article-title>
<source/><italic>J. Intellect. Disabil. Res.</italic>
<volume>40</volume>
<fpage>82</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2788.1996.tb00607.x</pub-id><pub-id pub-id-type="pmid">8930062</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steele</surname><given-names>T. D.</given-names></name><name><surname>Nichols</surname><given-names>D. E.</given-names></name><name><surname>Yim</surname><given-names>G. K.</given-names></name></person-group> (<year>1987</year>). <article-title>Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain.</article-title>
<source/><italic>Biochem. Pharmacol.</italic>
<volume>36</volume>
<fpage>2297</fpage>–<lpage>2303</lpage>. <pub-id pub-id-type="doi">10.1016/0006-2952(87)90594-6</pub-id><pub-id pub-id-type="pmid">2886126</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sulzer</surname><given-names>D.</given-names></name><name><surname>Sonders</surname><given-names>M. S.</given-names></name><name><surname>Poulsen</surname><given-names>N. W.</given-names></name><name><surname>Galli</surname><given-names>A.</given-names></name></person-group> (<year>2005</year>). <article-title>Mechanisms of neurotransmitter release by amphetamines: a review.</article-title>
<source/><italic>Prog. Neurobiol.</italic>
<volume>75</volume>
<fpage>406</fpage>–<lpage>433</lpage>. <pub-id pub-id-type="doi">10.1016/j.pneurobio.2005.04.003</pub-id>
<pub-id pub-id-type="pmid">15955613</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sungur</surname><given-names>A. Ö.</given-names></name><name><surname>Jochner</surname><given-names>M. C. E.</given-names></name><name><surname>Harb</surname><given-names>H.</given-names></name><name><surname>Kılıç</surname><given-names>A.</given-names></name><name><surname>Garn</surname><given-names>H.</given-names></name><name><surname>Schwarting</surname><given-names>R. K. W.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Aberrant cognitive phenotypes and altered hippocampal BDNF expression related to epigenetic modifications in mice lacking the post-synaptic scaffolding protein SHANK1: implications for autism spectrum disorder.</article-title>
<source/><italic>Hippocampus</italic>
<volume>27</volume>
<fpage>906</fpage>–<lpage>919</lpage>. <pub-id pub-id-type="doi">10.1002/hipo.22741</pub-id>
<pub-id pub-id-type="pmid">28500650</pub-id></mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sungur</surname><given-names>A. Ö.</given-names></name><name><surname>Schwarting</surname><given-names>R. K. W.</given-names></name><name><surname>Wöhr</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Early communication deficits in the SHANK1 knockout mouse model for autism spectrum disorder: developmental aspects and effects of social context.</article-title>
<source/><italic>Autism Res.</italic>
<volume>9</volume>
<fpage>696</fpage>–<lpage>709</lpage>. <pub-id pub-id-type="doi">10.1002/aur.1564</pub-id>
<pub-id pub-id-type="pmid">26419918</pub-id></mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sungur</surname><given-names>A. Ö.</given-names></name><name><surname>Schwarting</surname><given-names>R. K. W.</given-names></name><name><surname>Wöhr</surname><given-names>M.</given-names></name></person-group> (<year>2018</year>). <article-title>Behavioral phenotypes and neurobiological mechanisms in the SHANK1 mouse model for autism spectrum disorder: a translational perspective.</article-title>
<source/><italic>Behav. Brain Res.</italic>
<volume>352</volume>
<fpage>46</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2017.09.038</pub-id>
<pub-id pub-id-type="pmid">28963042</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sungur</surname><given-names>A. Ö.</given-names></name><name><surname>Vörckel</surname><given-names>K. J.</given-names></name><name><surname>Schwarting</surname><given-names>R. K. W.</given-names></name><name><surname>Wöhr</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Repetitive behaviors in the SHANK1 knockout mouse model for autism spectrum disorder: developmental aspects and effects of social context.</article-title>
<source/><italic>J. Neurosci. Methods</italic>
<volume>234</volume>
<fpage>92</fpage>–<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneumeth.2014.05.003</pub-id>
<pub-id pub-id-type="pmid">24820912</pub-id></mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ting</surname><given-names>J. T.</given-names></name><name><surname>Peça</surname><given-names>J.</given-names></name><name><surname>Feng</surname><given-names>G.</given-names></name></person-group> (<year>2012</year>). <article-title>Functional consequences of mutations in postsynaptic scaffolding proteins and relevance to psychiatric disorders.</article-title>
<source/><italic>Annu. Rev. Neurosci.</italic>
<volume>35</volume>
<fpage>49</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-neuro-062111-150442</pub-id>
<pub-id pub-id-type="pmid">22540979</pub-id></mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Buuse</surname><given-names>M.</given-names></name><name><surname>Ruimschotel</surname><given-names>E.</given-names></name><name><surname>Martin</surname><given-names>S.</given-names></name><name><surname>Risbrough</surname><given-names>V. B.</given-names></name><name><surname>Halberstadt</surname><given-names>A. L.</given-names></name></person-group> (<year>2011</year>). <article-title>Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT(1A) receptor knockout mice: implications for schizophrenia.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>61</volume>
<fpage>209</fpage>–<lpage>216</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.04.001</pub-id>
<pub-id pub-id-type="pmid">21501627</pub-id></mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verhoeven</surname><given-names>W. M.</given-names></name><name><surname>Egger</surname><given-names>J. I.</given-names></name><name><surname>Willemsen</surname><given-names>M. H.</given-names></name><name><surname>de Leijer</surname><given-names>G. J.</given-names></name><name><surname>Kleefstra</surname><given-names>T.</given-names></name></person-group> (<year>2012</year>). <article-title>Phelan-McDermid syndrome in two adult brothers: atypical bipolar disorder as its psychopathological phenotype?</article-title>
<source/><italic>Neuropsychiatr. Dis. Treat.</italic>
<volume>8</volume>
<fpage>175</fpage>–<lpage>179</lpage>. <pub-id pub-id-type="doi">10.2147/NDT.S30506</pub-id>
<pub-id pub-id-type="pmid">22570549</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verhoeven</surname><given-names>W. M. A.</given-names></name><name><surname>Egger</surname><given-names>J. I. M.</given-names></name><name><surname>Cohen-Snuijf</surname><given-names>R.</given-names></name><name><surname>Kant</surname><given-names>S. G.</given-names></name><name><surname>de Leeuw</surname><given-names>N.</given-names></name></person-group> (<year>2013</year>). <article-title>Phelan-McDermid syndrome: clinical report of a 70-year-old woman.</article-title>
<source/><italic>Am. J. Med. Genet. A</italic>
<volume>161</volume>
<fpage>158</fpage>–<lpage>161</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.35597</pub-id>
<pub-id pub-id-type="pmid">23166010</pub-id></mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vucurovic</surname><given-names>K.</given-names></name><name><surname>Landais</surname><given-names>E.</given-names></name><name><surname>Delahaigue</surname><given-names>C.</given-names></name><name><surname>Eutrope</surname><given-names>J.</given-names></name><name><surname>Schneider</surname><given-names>A.</given-names></name><name><surname>Leroy</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Bipolar affective disorder and early dementia onset in a male patient with SHANK3 deletion.</article-title>
<source/><italic>Eur. J. Med. Genet.</italic>
<volume>55</volume>
<fpage>625</fpage>–<lpage>629</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmg.2012.07.009</pub-id>
<pub-id pub-id-type="pmid">22922660</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Gallegos</surname><given-names>D. A.</given-names></name><name><surname>Pogorelov</surname><given-names>V. M.</given-names></name><name><surname>O’Hare</surname><given-names>J. K.</given-names></name><name><surname>Calakos</surname><given-names>N.</given-names></name><name><surname>Wetsel</surname><given-names>W. C.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Parvalbumin interneurons of the mouse nucleus accumbens are required for amphetamine-induced locomotor sensitization and conditioned place preference.</article-title>
<source/><italic>Neuropsychopharmacology</italic>
<volume>43</volume>
<fpage>953</fpage>–<lpage>963</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2017.178</pub-id>
<pub-id pub-id-type="pmid">28840858</pub-id></mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>McCoy</surname><given-names>P. A.</given-names></name><name><surname>Rodriguiz</surname><given-names>R. M.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Je</surname><given-names>H. S.</given-names></name><name><surname>Roberts</surname><given-names>A. C.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of SHANK3.</article-title>
<source/><italic>Hum. Mol. Genet.</italic>
<volume>20</volume>
<fpage>3093</fpage>–<lpage>3108</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddr212</pub-id>
<pub-id pub-id-type="pmid">21558424</pub-id></mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>S. R.</given-names></name><name><surname>Duffy</surname><given-names>P.</given-names></name><name><surname>Kalivas</surname><given-names>P. W.</given-names></name></person-group> (<year>1994</year>). <article-title>Methylenedioxymethamphetamine depresses glutamate-evoked neuronal firing and increases extracellular levels of dopamine and serotonin in the nucleus accumbens in vivo.</article-title>
<source/><italic>Neuroscience</italic>
<volume>62</volume>
<fpage>41</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/0306-4522(94)90313-1</pub-id>
<pub-id pub-id-type="pmid">7816211</pub-id></mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>S. R.</given-names></name><name><surname>Obradovic</surname><given-names>T.</given-names></name><name><surname>Imel</surname><given-names>K. M.</given-names></name><name><surname>Wheaton</surname><given-names>M. J.</given-names></name></person-group> (<year>1996</year>). <article-title>The effects of methylenedioxymethamphetamine (MDMA, “Ecstasy”) on monoaminergic neurotransmission in the central nervous system.</article-title>
<source/><italic>Prog. Neurobiol.</italic>
<volume>49</volume>
<fpage>455</fpage>–<lpage>479</lpage>. <pub-id pub-id-type="doi">10.1016/0301-0082(96)00027-5</pub-id><pub-id pub-id-type="pmid">8895996</pub-id></mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willemsen</surname><given-names>M. H.</given-names></name><name><surname>Rensen</surname><given-names>J. H. M.</given-names></name><name><surname>van Schrojenstein-Lantman de Valk</surname><given-names>H. M. J.</given-names></name><name><surname>Hamel</surname><given-names>B. C. J.</given-names></name><name><surname>Kleefstra</surname><given-names>T.</given-names></name></person-group> (<year>2011</year>). <article-title>Adult phenotypes in angelman- and rett-like syndromes.</article-title>
<source/><italic>Mol. Syndromol.</italic>
<volume>2</volume>
<fpage>217</fpage>–<lpage>234</lpage>. <pub-id pub-id-type="doi">10.1159/000335661</pub-id>
<pub-id pub-id-type="pmid">22670143</pub-id></mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiltschko</surname><given-names>A. B.</given-names></name><name><surname>Pettibone</surname><given-names>J. R.</given-names></name><name><surname>Berke</surname><given-names>J. D.</given-names></name></person-group> (<year>2010</year>). <article-title>Opposite effects of stimulant and antipsychotic drugs on striatal fast-spiking interneurons.</article-title>
<source/><italic>Neuropsychopharmacology</italic>
<volume>35</volume>
<fpage>1261</fpage>–<lpage>1270</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2009.226</pub-id>
<pub-id pub-id-type="pmid">20090670</pub-id></mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wöhr</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Ultrasonic vocalizations in Shank mouse models for autism spectrum disorders: detailed spectrographic analyses and developmental profiles.</article-title>
<source/><italic>Neurosci. Biobehav. Rev.</italic>
<volume>43</volume>
<fpage>199</fpage>–<lpage>212</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2014.03.021</pub-id>
<pub-id pub-id-type="pmid">24726578</pub-id></mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wöhr</surname><given-names>M.</given-names></name><name><surname>Orduz</surname><given-names>D.</given-names></name><name><surname>Gregory</surname><given-names>P.</given-names></name><name><surname>Moreno</surname><given-names>H.</given-names></name><name><surname>Khan</surname><given-names>U.</given-names></name><name><surname>Vörckel</surname><given-names>K. J.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Lack of parvalbumin in mice leads to behavioral deficits relevant to all human autism core symptoms and related neural morphofunctional abnormalities.</article-title>
<source/><italic>Transl. Psychiatry</italic>
<volume>5</volume>:<issue>e525</issue>. <pub-id pub-id-type="doi">10.1038/tp.2015.19</pub-id>
<pub-id pub-id-type="pmid">25756808</pub-id></mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wöhr</surname><given-names>M.</given-names></name><name><surname>Roullet</surname><given-names>F. I.</given-names></name><name><surname>Hung</surname><given-names>A. Y.</given-names></name><name><surname>Sheng</surname><given-names>M.</given-names></name><name><surname>Crawley</surname><given-names>J. N.</given-names></name></person-group> (<year>2011</year>). <article-title>Communication impairments in mice lacking SHANK1: reduced levels of ultrasonic vocalizations and scent marking behavior.</article-title>
<source/><italic>PLoS One</italic>
<volume>6</volume>:<issue>e20631</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0020631</pub-id>
<pub-id pub-id-type="pmid">21695253</pub-id></mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Won</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>H. R.</given-names></name><name><surname>Gee</surname><given-names>H. Y.</given-names></name><name><surname>Mah</surname><given-names>W.</given-names></name><name><surname>Kim</surname><given-names>J. I.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Autistic-like social behaviour in SHANK2-mutant mice improved by restoring NMDA receptor function.</article-title>
<source/><italic>Nature</italic>
<volume>486</volume>
<fpage>261</fpage>–<lpage>265</lpage>. <pub-id pub-id-type="doi">10.1038/nature11208</pub-id>
<pub-id pub-id-type="pmid">22699620</pub-id></mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>F.</given-names></name><name><surname>Gainetdinov</surname><given-names>R. R.</given-names></name><name><surname>Wetsel</surname><given-names>W. C.</given-names></name><name><surname>Jones</surname><given-names>S. R.</given-names></name><name><surname>Bohn</surname><given-names>L. M.</given-names></name><name><surname>Miller</surname><given-names>G. W.</given-names></name><etal></etal></person-group> (<year>2000</year>). <article-title>Mice lacking the norepinephrine transporter are supersensitive to psychostimulants.</article-title>
<source/><italic>Nat. Neurosci.</italic>
<volume>3</volume>
<fpage>465</fpage>–<lpage>471</lpage>. <pub-id pub-id-type="doi">10.1038/74839</pub-id>
<pub-id pub-id-type="pmid">10769386</pub-id></mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Vorhees</surname><given-names>C. V.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name></person-group> (<year>2000</year>). <article-title>Behavioral responses to cocaine and amphetamine administration in mice lacking the dopamine D1 receptor.</article-title>
<source/><italic>Brain Res.</italic>
<volume>852</volume>
<fpage>198</fpage>–<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-8993(99)02258-1</pub-id>
<pub-id pub-id-type="pmid">10661513</pub-id></mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>B. K.</given-names></name><name><surname>Spanos</surname><given-names>L. J.</given-names></name></person-group> (<year>1988</year>). <article-title>The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat.</article-title>
<source/><italic>Eur. J. Pharmacol.</italic>
<volume>148</volume>
<fpage>195</fpage>–<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1016/0014-2999(88)90564-X</pub-id>
<pub-id pub-id-type="pmid">2897922</pub-id></mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Jiang</surname><given-names>Y. H.</given-names></name></person-group> (<year>2018</year>). <article-title>SHANK2 harbors potentially pathogenic mutations associated with bipolar disorder.</article-title>
<source/><italic>Bipolar Disord.</italic>
<volume>20</volume>
<fpage>63</fpage>–<lpage>141</lpage>. <pub-id pub-id-type="doi">10.1111/bdi.12619</pub-id></mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>J.</given-names></name><name><surname>Bakes</surname><given-names>J.</given-names></name><name><surname>Bradley</surname><given-names>C.</given-names></name><name><surname>Collingridge</surname><given-names>G. L.</given-names></name><name><surname>Kaang</surname><given-names>B. K.</given-names></name></person-group> (<year>2013</year>). <article-title>Shank mutant mice as an animal model of autism.</article-title>
<source/><italic>Philos. Trans. R. Soc. Lond. B Biol. Sci.</italic>
<volume>369</volume>:<issue>20130143</issue>. <pub-id pub-id-type="doi">10.1098/rstb.2013.0143</pub-id>
<pub-id pub-id-type="pmid">24298145</pub-id></mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>J. W.</given-names></name><name><surname>Goey</surname><given-names>A. K. L.</given-names></name><name><surname>Minassian</surname><given-names>A.</given-names></name><name><surname>Perry</surname><given-names>W.</given-names></name><name><surname>Paulus</surname><given-names>M. P.</given-names></name><name><surname>Geyer</surname><given-names>M. A.</given-names></name></person-group> (<year>2010</year>). <article-title>GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior.</article-title>
<source/><italic>Psychopharmacology</italic>
<volume>208</volume>
<fpage>443</fpage>–<lpage>454</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-009-1744-8</pub-id>
<pub-id pub-id-type="pmid">20020109</pub-id></mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>J. W.</given-names></name><name><surname>Henry</surname><given-names>B. L.</given-names></name><name><surname>Geyer</surname><given-names>M. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Predictive animal models of mania: hits, misses and future directions.</article-title>
<source/><italic>Br. J. Pharmacol.</italic>
<volume>164</volume>
<fpage>1263</fpage>–<lpage>1284</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01318.x</pub-id>
<pub-id pub-id-type="pmid">21410454</pub-id></mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Need</surname><given-names>A. C.</given-names></name><name><surname>Petrovski</surname><given-names>S.</given-names></name><name><surname>Goldstein</surname><given-names>D. B.</given-names></name></person-group> (<year>2014</year>). <article-title>One gene, many neuropsychiatric disorders: lessons from Mendelian diseases.</article-title>
<source/><italic>Nat. Neurosci.</italic>
<volume>17</volume>
<fpage>773</fpage>–<lpage>781</lpage>. <pub-id pub-id-type="doi">10.1038/nn.3713</pub-id>
<pub-id pub-id-type="pmid">24866043</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>